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1. Introduction
Over the past 20 years, the growth of nanomaterials research 
has been concomitant with an overwhelming increase in 
the production of nanotechnology-related products.[1,2] This 
increased attention in the industry is also reflected in the 
amount of nanomaterials (i.e., a material 
with one, two, or three external dimen-
sions on the nanoscale (<100 nm)), pro-
duced annually, which has reached values 
of over 1000 tons for some materials.[3,4] 
This new industrial revolution prom-
ises to provide an advantageous basis for 
numerous applications, including medi-
cine (e.g., drug delivery, imaging, and 
theranostics), consumer products (e.g., 
food additives, cosmetics, and sporting 
equipment), environmental remediation, 
and information technology.[2]
The implementation of nanomaterials 
in the medical field allows a variety of 
biomedical applications, for instance as 
diagno stic or therapeutic agents and in 
novel vaccine formulations.[5]
The advantages of such nanomaterials 
are diverse and include: (i) their small 
size, which is in the range of biomolecules 
(e.g., receptors, antibodies, or nucleic 
acids) and enables interactions with single 
cells; (ii) their highly tunable surfaces for 
functionalization’s with biomolecules, which enables targeting 
of cells and/or intracellular organelles; (iii) their high surface 
area, which allows the attachment of more drug units than on 
larger particles of the same total mass, thus leading to higher 
loading efficacy; and (iv) their distinctive physicochemical prop-
erties when compared to their bulk materials, which can pro-
vide potential opportunities, for example in hyperthermia treat-
ments.[6] In the last decade, a broad array of new and improved 
nanoscale materials has emerged, some of which draw inspi-
ration for their design from nature. In a broad context, they 
are defined as materials that imitate key features of natural 
materials and/or biological structures at the chemical, physical, 
or morphological level. The list of such bioinspired materials 
includes systems based on lipids (e.g., liposomes), glycans 
(e.g., sugars), peptides, nucleic acids, and dendrimers, among 
others.[7] There have been major advances in the engineering of 
biomimetic nanomaterials that replicate features of bio logical 
systems and surfaces that mimic natural cells and viruses, 
such as long circulation times, few interactions with off-target 
molecules, and high-affinity targeting of specific cells.[8,9] These 
benefits add to the already interesting properties that come 
from the nanoscale of the material.
Despite all these interesting properties and technology 
advancements, very few nanomaterials have been approved by 
Realization of the immense potential of nanomaterials for biomedical appli-
cations will require a thorough understanding of how they interact with cells, 
tissues, and organs. There is evidence that, depending on their physico-
chemical properties and subsequent interactions, nanomaterials are indeed 
taken up by cells. However, the subsequent release and/or intracellular deg-
radation of the materials, transfer to other cells, and/or translocation across 
tissue barriers are still poorly understood. The involvement of these cellular 
clearance mechanisms strongly influences the long-term fate of used nano-
materials, especially if one also considers repeated exposure. Several nano-
materials, such as liposomes and iron oxide, gold, or silica nanoparticles, are 
already approved by the American Food and Drug Administration for clinical 
trials; however, there is still a huge gap of knowledge concerning their fate in 
the body. Herein, clinically relevant nanomaterials, their possible modes of 
exposure, as well as the biological barriers they must overcome to be effective 
are reviewed. Furthermore, the biodistribution and kinetics of nanomaterials 
and their modes of clearance are discussed, knowledge of the long-term fates 
of a selection of nanomaterials is summarized, and the critical points that 
must be considered for future research are addressed.
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the Food and Drug Administration (FDA) for use in medical 
applications, whereas the majority have thus far failed to reach 
the bedside.[10] Therefore, new efforts have to focus on a detailed 
understanding of the interaction of nanomaterials with the 
cells at the fundamental level. To further increase the number 
of nanomaterial systems that reach clinical applications, it is 
important to address the possible biodistribution, clearance 
routes, and the long-term fate of these nanomaterials in the 
body. So far, little effort has been put in to studying the fate of 
nanomaterials over more than a few days, due to the limited 
detection possibilities currently available. Another reason might 
be the difficulty in the controlled production of the nanomate-
rials, for example producing materials with low polydispersity. 
This seems to be especially challenging when the production is 
upscaled to an industrial scale.[11,12]
Despite major drawbacks, a number of nanomaterials are 
currently being tested in preclinical and clinical phases, cov-
ering a broad spectrum from polymers, liposomes, micelles, 
nanocrystals, and protein-based nanomaterials to inorganic 
nanomaterials (for a review see ref. [13]). A recent review 
from 2016 identified around 51 FDA-approved nanomedicines 
and around 77 products in clinical trials.[14] These approved 
materials include gold nanoparticles (AuNPs) that, given their 
biologically inert properties, provide a good basis for nanosized 
drug delivery systems.[15,16] Additionally, a range of nanobased 
drug delivery systems, such as liposomal, polymeric, or bio-
inspired nanoparticles (NPs), have already progressed into ther-
apeutic applications.[17–19] Other promising classes of materials 
are quantum dots (QDs), semiconducting nanocrystals 
that contain properties suitable for imaging and diagnostic 
appli cations.[20] Even though QDs have successfully been 
applied as an imaging tool and provided valuable data on the 
behavior of nanomaterials and interactions in vivo (e.g., renal 
clearance), their clinical applicability remains controversial due 
to their potential health risks and demonstrated toxicity.[21–24] 
Furthermore, the already FDA-approved superparamagnetic iron 
oxide nanoparticles (SPIONs), i.e., NanoTherm, have drawn 
attention for their possible hyperthermal treatment of cancer 
when exposed to an alternating magnetic field, in addition to 
being useful as a classical drug or a gene delivery system.[25,26]
The aim of this review is to address the long-term biological 
fate of clinically interesting nanomaterials and present exam-
ples of materials for which reliable data have been found. We 
discuss the possible administration routes of nanomaterials 
and how their properties (e.g., size, surface charge, and func-
tionalization) can affect their interaction at the tissue and cell 
membranes, their uptake and intracellular fate at the single cell 
level, as well as their biodistribution and clearance in vivo.
2. Therapeutic Nanomaterials—Possible Routes 
of Exposure
2.1. Modes of Exposure
To exert its mode of action, a drug or active agent needs to reach 
the organ, tissue or cell of interest. Over the course of time, 
different approaches have been established in order to increase 
targeting efficiency. In this review, we focus on the exposure 
routes most commonly used for nanomaterials, and their 
respective implications, by considering the subsequent fate 
of the administered nanomaterial. We not only consider the 
literature available describing the intentional application of 
biomedical nanomaterials, but also the much more extensive 
body of literature describing hazard/risk assessment results 
for the unintentional exposure of humans to nanomaterials. 
An overview of the commonly used routes of exposure can be 
found in Figure 1.
2.2. Injection
The most direct route of administration of nanomaterials is via 
injection. The most commonly practiced routes include intrave-
nous, subcutaneous, and intratumoral injection. The advantage 
of the direct injection of nanomaterials into the bloodstream is 
the rapid delivery and distribution of the materials throughout 
the vasculature. However, one has to consider that this rapid 
distribution of the materials also results in their clearance by 
the kidneys, the liver, or via the reticuloendothelial system 
(RES). For the metabolism of conventional drugs, the liver is 
paramount. This effect, also known as the first-pass effect, can 
be used to engineer a nanomaterial or nanocarrier in such a 
way that the material or carried drug is only activated in the 
liver,[27] or nanomaterials can be designed so as to overcome 
the first-pass effect in the liver. The aforementioned limita-
tions can be circumvented by subcutaneous or intratumoral 
injection, which then means that the location of the injection 
has to be carefully chosen for optimal effect. The fate of the 
nanomaterials after subcutaneous injection heavily depends on 
the interstitial lymphatic flow rate at the site of the injection 
and on the physicochemical properties of the nanomaterials. 
The major factor is size, as small colloids (smaller than a few 
nanometers) are mostly absorbed into capillaries, while nano-
materials up to a few scores of nanometers cannot be similarly 
absorbed and are instead drained into the lymphatic system. 
It has been shown that larger materials can persist longer 
at the injection site.[28] Finally, nanomaterials can also be 
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injected directly into tumor tissues, which is currently the most 
frequently used route in animal experimentation, as this seems 
to be the most promising route for successful implementation in 
patients. This approach overcomes the limitations arising from 
systemic administration, and targeting can also be optimized 
by delivering the nanomaterial directly to the interstitium of 
the cancerous tissue.[29] The parameters influencing the subse-
quent fate of the nanomaterials are similar to those described 
for the subcutaneous injection route. However, the interstitial 
pressure in tumors has been found to be higher than in healthy 
tissue, leading to a generally higher leakage of the drugs 
into the surrounding tissue.[30] Despite its advantages and 
successes, intratumoral injection is only applicable for easily 
accessible tumors.
2.3. Inhalation
Another promising and direct route for the administration of 
nanomaterials is via inhalation, either for the treatment of lung 
diseases or for systemic delivery. It was shown as early as the 
1920s that inhaled insulin can lower blood sugar.[31] The lung 
has very interesting structure-functional properties, such as 
a huge internal surface area of about 150 m2 (i.e., alveoli and 
airways)[32] and high endothelial permeability. These features 
facilitate systemic delivery and thus make the lung a promising 
organ for nanomaterial administration.[33]
Based on the particle size, it can be predicted in which com-
partment particles will predominantly deposit in the lung. 
The smaller the particles are, the deeper they penetrate into 
the lung parenchyma.[34,35] However, it has also be shown that 
nanomaterials can deposit into the olfactory epithelium and 
directly translocate to the brain.[36] Inhaled nanomaterials are 
subject to different clearing mechanisms depending on the pul-
monary compartment in which they are deposited. In the large 
airways, the mucociliary escalator provides rapid clearance of 
deposited materials. In contrast, nanomaterials that reach the 
gas-exchange region will be cleared less rapidly by alveolar 
macrophages, i.e., professional phagocytes, which may migrate 
out of the lung or remain in the pulmonary interstitium, or 
by dendritic cells, professional antigen-presenting cells, with 
subsequent transport to the lung-draining lymph nodes. Irre-
spective of the pulmonary compartment, nanomaterials can 
also be taken up by pulmonary epithelial cells and they may 
translocate across the epithelial barrier (transcytosis). In the 
case of an alveolar epithelium that is extremely thin, this pro-
cess may lead to translocation into the blood stream.[37–39] All 
of these mechanisms by which the nanomaterials interact and 
are cleared by the respiratory tract have to be taken into account 
for the design of new inhaled nanomaterials/nanocarriers.[40,41]
A good example of such application has been shown by 
Bianchi et al.[42] They reported that the retention of gado-
linium-based theranostic nanoparticles as contrast agents, 
administered via inhalation, shows some direct advantages, 
e.g., high retention in lung tumor tissue, in comparison 
to the classical intravenous injection route. This work was 
then followed up by Dufort et al. who showed that those 
nanoparticles do not induce inflammation and would be fit 
for use not only as contrast agents but also as therapeutic 
carriers.[43]
However, conflicting reports exist as to what proportions 
of nanomaterials can be systemically found after inhala-
tion, showing major differences between animal and human 
models.[44] Addressing this divergence is of great importance, 
as the inhalation of nanoscale particulates is also of major 
concern with respect to their unintentional inhalation.[45]
Figure 1. Routes of administration: summary of the routes of exposure commonly used for nanomaterial administration, including their main 
advantages (green) and challenges (red).
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2.4. Oral Administration
Oral administration of nanotherapeutics is the most preferred 
method of delivery, particularly due to its relatively convenient 
application and consequently its relatively high patient compli-
ance.[46] Very few nanomaterial-based systems with the poten-
tial to be used as oral drugs (e.g., immunosuppressants and 
antiretrovirals) have been described thus far. Although this 
route is the most favorable one, the accompanying enzymatic 
degradation, the acidic environment in the stomach, and the 
poor penetration across the intestinal tissue barrier all result in 
poor oral bioavailability.[46] These challenges render the trans-
lation from benchtop to the clinic more difficult.[47] However, 
it has been shown that nanomaterial formulations can enhance 
the bioavailability of orally administered drugs.[47]
More knowledge about the interaction of nanomaterials with 
the gastrointestinal tract can be obtained from nanomaterials 
found in food or food packaging since most of these materials 
are metallic oxides and can be analyzed more easily. The Project 
on Emerging Nanotechnologies currently lists 118 nanotechnology-
containing items in the Food and Beverage category, predomi-
nantly silver, nanosilicates, and titanium dioxide.[48] Silver (Ag) 
nanoparticles are mostly used for their antibacterial properties in 
packaging, and it has been shown that these particles can leach 
out from the packaging material over time.[49] In this context, 
silica (SiO2) (E551) and titanium dioxide TiO2 (E171) NPs in par-
ticular should be noted since they have already been approved 
as dietary additives (anticaking and food whitening/brightening, 
respectively). The available toxicity data have recently been 
reviewed by McCracken et al.[50] Briefly, the available in vivo data 
of rats and mice are inconclusive for SiO2NPs.[50] Some studies 
state very little absorption of ingested NPs, whereas others state 
toxic effects. For TiO2 NPs the data are similarly inconclusive, 
with some studies not finding any absorption or acute toxicity, 
while others do.[50]
2.5. Dermal Administration
The skin is the largest organ in humans and provides an 
effective barrier toward the environment. Recent reviews have 
addressed the potential interaction of nanomaterials with the 
skin barrier.[51,52]
A major function of the skin, particularly the stratum 
corneum (the outermost layer), is to provide a protective bar-
rier against the hazardous external environment. The skin is 
relatively impenetrable to lipophilic molecules larger than 
600 Da in molecular weight, whereas lipophilic particles 
smaller than this may passively penetrate.[53] In addition, it is 
also a potential target for drug delivery via nanocarriers.[54]
Many commercially available sunscreens contain TiO2  
and zinc oxide (ZnO) NPs because of their UV scattering and 
reflecting properties, which attenuate harmful solar radi ation 
reaching the skin.[55] It has been shown that the presence 
of TiO2 NPs, in combination with sunlight, can have adverse 
effects on DNA.[56] However, the current common consensus in 
the field is that the NPs present in sunscreen do not penetrate 
healthy or sunburnt skin.[55,57] Minor skin disruptions or psori-
asis do not change this; only conditions disrupting the stratum 
corneum (e.g., eczema) have been found to increase penetra-
tion of the aforementioned particles.[57]
It has also recently been demonstrated that nanoparticles 
originating from tattoo ink can migrate to lymph nodes and 
persist for extended periods of time.[58]
In general, it can be stated that healthy human skin is an 
efficient barrier against the most frequently applied NPs, such 
as the ZnO or TiO2 particles in cosmetics.[59,60] Because of the 
barrier properties of the skin, NP formulations for systemic 
delivery are not very promising. On the other hand, nano-
material formulations for the treatment of topical conditions 
(e.g., psoriasis) have been more heavily investigated.[61] 
The review of Yang et al. addresses drug delivery across the 
skin barrier in a complete and detailed manner.[62]
2.6. Other Administration Routes
Other application routes involve the retinal application of diffe-
rent formulations for drug delivery. Through optimization of 
the design of the nanomaterials used as future drug carriers, 
their inherently low bioavailability could be partially improved, 
as manifested by a number of formulations reaching clinical 
trials for eye applications. Some examples of this are hydrogel 
formulations for the topical treatment of ocular hypertension 
and cyclodextrin-based eye drops for open-angle glaucoma.[63] 
Another possibility is the coating of implants with Ag NPs, 
which have antibacterial properties.[64] It has been shown 
that implants treated with Ag NPs are biocompatible and 
show promising results toward the attenuation of infectious 
diseases.[65,66]
Furthermore, a number of ongoing projects are concerned 
with the application of nanomaterials as delivery systems to 
overcome mucosal barriers, such as those of the nose or mouth. 
There are a variety of benefits of nasal application for a patient, 
for instance the high total blood flow per unit of surface area, 
easy accessibility, and the direct transport of drugs to the brain 
via the olfactory nerves.[67] Currently, efforts are concentrated 
on bypassing the very selectively permeable blood–brain barrier 
(BBB) and thereby delivering drugs directly into the brain.[68] 
However, the efficacy of this route is yet to be experimentally 
proven.[68,69] In comparison, most of the research into the 
buccal administration route is performed in order to increase 
retention time and to increase mucoadhesion so as to prevent 
the drug from being washed away by saliva.[70,71] However, this 
field has not yet been comprehensively explored.
The review of Kermanizadeh et al. gives a good overview of 
different exposure routes and the possible adverse effects 
of nanoparticles following such administrations.[72]
2.7. Protein Corona
As elaborated above, nanomaterials may be administered to 
the human body via different methods such as by inhalation, 
injection, ingestion, and application to the skin. Independent 
of the administration route, the particles inevitably encounter a 
complex physiological fluid environment populated with a wide 
range of biomacromolecules, e.g., proteins, vitamins, lipids, 
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and salts/ions.[73] Upon contact with physiological fluids, the 
formation of a surface-bound protein layer, particle dissolution, 
or aggregation might occur, which are expected to have a 
crucial impact on cellular, tissue, and organ interaction.[74] 
For the subsequent fate it is important to understand the conse-
quences of the interactions of nanomaterials with physiological 
fluids including mucus (gastrointestinal (GI) or respiratory 
tract), aqueous lining layer covered by surfactant (lung paren-
chyma), the blood or the lymphatic fluid, as well as available 
analytical methods to investigate the possible interactions.[75]
The description of the protein corona formation depending 
on the physicochemical properties of the nanomaterials is 
beyond the scope of this review and has been thoroughly pre-
sented elsewhere.[76–82] We have, however, included relevant 
literature for the later discussed materials.
3. Biological Barriers
3.1. Tissue Barriers
A variety of biological barriers exist, and nanomaterials or drug 
nanocarriers must either be designed to be effective at the dis-
eased barrier itself or to overcome the barrier to provide an 
effective concentration of the therapeutic drug at the diseased 
site. Depending on the mode of exposure and the route of 
administration, external and internal biological barriers can be 
differentiated.
The skin and the mucosa form primary structural barriers 
that separate the hosts from the external environment. External 
barriers include the epithelia of the skin, the nasal tract and the 
respiratory system, the retina, and the gastrointestinal tract. 
The stratum corneum comprises the physical barrier of the 
skin, whereas the other barriers are covered with a mucosal 
layer that has to be overcome by a nanomaterial via the afore-
mentioned exposure routes in order to reach the blood circulation 
and/or the targeted tissue.
Internal or secondary biological barriers include the 
endothelium of the blood vessels, the BBB, the blood–testis 
barrier (BTB), the placental barrier, the interstitial space and 
extracellular matrix (ECM), and reticuloendothelial system.
Normally, blood endothelial tissue is tight and does not 
allow nanomaterials to translocate. However, cancerous 
tissue, as well as inflammatory reactions causing activation 
and secretion of proinflammatory cytokines (tumor necrosis 
factor (TNF), interleukin (IL)-1, IL-6, vascular endothe-
lial growth factor (VEGF)), shows induction of endothelial 
fenestration, i.e., a loss of cellular integrity inducing a gap 
between the endothelial cells.[83,84] This feature can enable 
the nanomaterials to extravasate from the blood system into 
the cancerous and/or inflamed tissue. Another possibility 
is the clearance of the nanomaterials via the lymph system. 
After extravasation of nanomaterials from the blood system, 
they face the dense interstitial space and ECM, a network of 
collagen, proteins, and elastic fibers that provide the struc-
tural integrity to the tissue.[85,86] Diseases such as cancer 
and liver fibrosis reveal an altered ECM and an increased 
number of fibroblasts, which affect the penetration of nano-
materials through the tissue.[87]
The BBB, which is one of the tightest barriers in the human 
body, protects the central nervous system from toxins and 
restricts the diffusion of large, hydrophilic molecules into the 
cerebrospinal fluid. The efficient BBB is formed by endothe-
lial cells, the capillary basement membrane, astrocyte end-feet 
encircling the vessels, and pericytes forming an additional 
continuous layer that separates the blood vessels from brain 
tissue.[88] The endothelial cells from the BBB differ from 
endothelial cells found in the rest of the body since they show 
no fenestrations, form very tight monolayers (>1000 Ω cm2), 
and exhibit reduced pinocytotic vesicular transport.[89] It has 
been shown that only small lipophilic molecules and molecules 
with molecular weights less than 400 Da can diffuse through 
the BBB.[90] Specific brain pathologies, e.g., stroke, and Alzhei-
mer’s and Parkinson’s diseases, can cause an impairment of 
the BBB, making it more permeable to different molecules that 
can induce inflammatory responses or neuronal damage.[91] 
Despite this increased permeability, challenges for the efficient 
delivery of nanomaterials into the brain still remain.
The BTB protecting the male germ line is also one of the 
tightest blood–tissue barriers in the mammalian body. The BTB 
regulates the entry of nutrients (e.g., sugars and amino acids) 
and vital molecules (e.g., hormones and electrolytes) into the 
compartment that is important for sperm cell development.[92] 
Male germ cells are protected from harmful substances by 
Sertoli cells forming the BTB.[93] Sertoli cells are connected by 
basal ectoplasmic specializations, gap junctions, and desmosome-
like junctions.[94] Lan et al. have proposed that nanomaterials 
can display adverse effects on spermatogenesis by activating the 
release of (pro-)inflammatory cytokines, leading to a weakening 
of the BTB that allows the nanomaterials to cross the barrier.[95]
In females, the placenta protects the developing fetus during 
pregnancy and also changes its properties, such as thickness and 
permeability, during pregnancy. During the early days of preg-
nancy, an epithelial cell called a syncytiotrophoblast is formed, 
which represents the primary barrier between fetal and maternal 
tissue. Both the syncytiotrophoblast and the fetal capillary endothe-
lium express a variety of transporters that take part in drug trans-
port.[96,97] During the first trimester the barrier is thicker and less 
permeable than during the last three months, whereupon it gets 
thinner, more permeable, and therefore increases the chances of 
nanomaterials crossing the membrane. Exposure to nanomate-
rials in the third trimester can potentially cause severe damage 
to the placenta and a high possibility of miscarriage and embryo 
malformation.[98] However, newly engineered nanomaterial-based 
drug delivery systems could enable new therapeutic approaches 
during pregnancy to treat a diseased embryo/fetus in situ.
Another possibility is the clearance of the nanomaterials 
via the lymph system. After extravasation of nanomaterials 
from the blood system, they face the dense interstitial space 
and ECM, a network of collagen, proteins, and elastic fibers 
that provide the structural integrity to the tissue.[68,69] Diseases 
such as cancer and liver fibrosis reveal an altered ECM and an 
increased number of fibroblasts, which affect the penetration of 
nanomaterials through the tissue.[70] Furthermore, nanoparticles 
can be cleared by the RES. The RES is part of the immune system 
and contains monocytes and macrophages located in the various 
tissues, which retain and rapidly remove nanomaterials from the 
blood circulation through opsonization.[82]
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The translocation of particles from one side of a tissue 
barrier to the other is a phenomenon observed in many 
different tissues and organs. How this transport works in detail, 
i.e., if the transport occurs by trans- or paracellular routes, and 
what determines the fate of the internalized particles, is not 
yet fully understood.[99,100] The size dependency for the trans-
location of gold (Au) NPs across the lung epithelium was also 
confirmed by Kreyling et al. in 2014.[101] The authors reported 
that, in rats, the size, the material, specific surface area, and 
surface charge are all essential factors, with smaller particles 
translocating more easily. Several in vitro studies have investi-
gated the internalization and translocation of polystyrene NPs 
in intestine cell monocultures and more complex human intes-
tinal cell models. Walczak et al. showed in 2015 that the translo-
cation of NPs across the intestinal barrier is dependent on their 
size, charge, and surface chemistry.[102] However, the surface 
chemistry seems more important, as the two types of negatively 
charged NPs investigated showed a greater than 30-fold differ-
ence in translocation.[103]
3.2. Cellular Barriers
Once nanomaterials have overcome the tissue barriers and 
reached their target cells, or if they interact with cells at the 
tissue barrier itself, several other barriers remain, including 
the outer cell membrane and the intracellular membranes 
surrounding the different compartments. The cell membrane 
consists of a phospholipid bilayer containing various lipids, 
carbohydrates, and membrane proteins, which regulate the 
entry of small and large molecules into the cell and are held 
together mainly by noncovalent interactions.[104] In cell mem-
branes, the lipid molecules are arranged as an ≈4–5 nm thick, 
continuous double layer that is not rigid but rather dynamic, 
serving as a relatively impermeable barrier to the passage of 
most water-soluble molecules.[105] The fluidity of the phospho-
lipid bilayer results in changes in the arrangement of the 
different components into a nonhomogenous distribution 
pattern, described as the fluid mosaic model by Singer and 
Nicolson in 1972.[106] Different cellular uptake routes exist for 
macromolecules or materials entering a cell, such as passive 
diffusion through the membrane, transport-mediated uptake 
via transmembrane proteins serving as pumps or channels, 
or catalyzing membrane-associated reactions and vesicular 
uptake mechanisms, including endocytotic processes such as 
pinocytosis and phagocytosis.[107–109]
Specific targeting of a diseased tissue or cell represents 
a major challenge for effective nanomaterial formulations. 
Targeting strategies involve either passive targeting, by the 
enhanced permeability and retention (EPR) effect through 
the increased permeability in the cancer vasculature, or active 
targeting, via receptor–ligand-mediated interactions for cell 
binding, or direct intraarterial injection into the diseased 
area.[110] A more detailed overview about the EPR effect for 
macromolecular therapeutics can be found in the review by 
Maeda et al.[111] Subsequent to internalization by cells, nano-
materials are eventually transported through endocytic vesicles 
to the lysosomes. The lysosomal compartment is a low-pH 
environment, which may lead to potential degradation of 
ingested nanomaterials; however, it also provides new oppor-
tunities such as the possibility of theranostic approaches or 
controlled or triggered drug release.[112] Carbon nanotubes 
(CNTs) show great potential as pH-sensitive nanocarriers in 
cancer therapy, as this nanomaterial shows enhanced release 
of conjugated drugs in low-pH environments. Consequently, 
with the help of CNTs an anthracycline drug like doxorubicin 
selectively becomes effective in the extracellular environ-
ment of tumors that show low pH or inside the lysosomal 
compartment of cancer cells following targeted uptake.[113,114] 
Various strategies are employed to address this issue, such 
as the implementation of fusogenic peptides or pH-sensitive 
nanomaterials.[115] Endosomal escape is one of the key chal-
lenges for the clinical application of therapeutic drug delivery 
to target cells with subsequent access to other compartments, 
e.g., mitochondria or cell nuclei. However, with the develop-
ment of medical science, the organelle-specific delivery of bio-
active molecules has become more important for achieving 
maximum therapeutic effect with minimum side effects and 
has emerged as a new research field for the development of 
future drug delivery systems.[116] Mitochondria are one of the 
main classes of organelles that mediate apoptosis. Their dys-
function can cause neurodegenerative and neuromuscular 
diseases, diabetes, obesity, and cancer.[117–119] Mitochondria 
are composed of two membranes, featuring a high membrane 
potential across the inner membrane and a protein import 
machinery at the outer membrane, both features being used 
as possible targeting strategies.[120] The nucleus presents a further 
important intracellular barrier, but nevertheless constitutes a pop-
ular target for drug delivery systems as it regulates gene expres-
sion and other cellular processes.[121,122] A range of drugs act on 
the DNA level, preventing its replication and decreasing or inhib-
iting gene transcription. The major barrier for nanomaterials 
targeting the nucleus is represented by the nuclear membrane 
pores, which prevent entry of NPs larger than 9 nm.[123]
4. Cellular Uptake and Fate of Nanomaterials
4.1. Nanomaterial Uptake
The uptake of nanomaterials by mammalian cells occurs 
mainly via endocytotic pathways. Two types of endocytosis are 
distinguished: pinocytosis (“cellular drinking”) involves the 
ingestion of fluid and molecules via small vesicles (<0.15 μm 
in diameter), whereas phagocytosis involves the ingestion 
of large particles, such as microorganisms and cell debris, 
at formations of large vesicles called phagosomes (generally 
>0.25 μm in diameter) (for reviews see refs. [124,125]). 
The term pinocytosis includes macropinocytosis, clathrin- and 
caveolin-mediated endocytosis, and clathrin- and caveolin- 
independent endocytosis.[124]
Phagocytosis is carried out by professional phagocytes 
(i.e., monocytes/macrophages, neutrophils, and dendritic 
cells), which form intracellular phagosomes. Macromolecule 
or particle internalization is initiated by the interaction with 
specific receptors on the surface of the phagocyte. This leads 
to the polymerization of actin filaments at the site of inges-
tion, i.e., membrane ruffling, and after internalization the 
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phagosome matures by a series of fusion and fission events 
with components of the endocytic pathway, culminating in the 
formation of the mature phagolysosome.[126] Macropinocytosis 
triggers actin formation and the macropinosomes form large 
intracellular vesicles. However, instead of invaginating a ligand-
coated particle, they collapse onto and fuse with the plasma 
membrane to generate large endocytic vesicles called macropi-
nosomes, which sample large volumes of extracellular milieu.
Caveolin-mediated endocytosis is mostly used for the trans-
port of serum proteins. Caveolae are static, flask-shaped invagi-
nations of the plasma membrane that are slow in uptake and 
are observed in several cell types, including capillary endothe-
lium, type I alveolar epithelial cells, smooth muscle cells, and 
fibroblasts.[124] This mechanism is generally connected to 
cholesterol-rich microdomains, called rafts, with a diameter 
of 40–50 nm.[127,128] Clathrin-mediated endocytosis is very well 
studied and is, like most pinocytic pathways, a form of receptor-
mediated endocytosis, which is in general very fast. It occurs 
in all mammalian cells and carries out the continuous uptake 
of essential nutrients, such as the cholesterol-laden low-density 
lipoprotein particles that bind to the low-density lipoprotein 
receptor and iron-laden transferrin that binds to transferrin 
receptors.[129,130]
The endocytosis of (nano)materials is not just one mecha-
nism, and depends on the physical interaction of the material 
with the cell wall, the material itself, and also the cell type. 
Different nanomaterial properties, such as size, shape, material, 
and surface coating, have an impact on which uptake mecha-
nism will be activated.[108,131,132] In addition, the cell type plays a 
significant role since each cell type might have different uptake 
mechanisms and can react differently to nanomaterials.[133,134]
All of the previously presented endocytic pathways have at 
least one aspect in common: that the internalized particle is 
ultimately located in an intracellular vesicle. However, studies 
have reported that the intracellular localization of nanomate-
rials of different materials is not membrane-bound, thus indi-
cating alternative pathways for particles to enter cells.[135–138] 
Among other possible mechanisms, passive diffusion through 
membrane pores and passive uptake by van der Waals or steric 
interactions (subsumed as adhesive interactions) are sug-
gested by the authors of these studies.[139] However, it is not yet 
known which chemical and physical properties of the cellular 
membrane and particles are responsible for the translocation 
of nanomaterials into cells, the nucleus and organelles, either 
in vitro or in vivo. It is, however, important to mention that 
the localization of nanomaterials in the cytosol is only rarely 
observed and the majority of nanomaterials are found inside 
vesicular structures.
4.2. Endosomal Maturation
After the cellular uptake, nanomaterials end up in endocytic 
vesicles that fuse together to form early endosomes (EE). There, 
a complex machinery sorts the vesicles according to the type of 
the internalized materials and membrane-associated proteins 
to mature either into k, translocation or degradation vesicles. 
EE allow for ≈10 min to fuse with other endocytic vesicles, 
and during this time the membrane and internal fluids are 
constantly recycled, while the cargo (such as nanomaterials 
or other particles, e.g., viruses) is retained inside.[140–143] The 
material that stays inside the vesicle is then destined to end up 
in the lysosome. This occurs by the maturation of the EE into 
late endosomes (LE), which starts by association of cytosolic 
proteins, the so-called retromer, with the outer surface of the 
EE membrane.[144] These proteins, with Rab5 being the major 
factor, are also important markers for clear identification of 
endosomal vesicles and can also be used to show nanomaterial 
internalization in endosomes by colocalization studies.[145,146] 
During this maturation, the EEs are constantly exchanging 
vesicles with the trans-Golgi network (TGN), which sends 
bi directional exchange crucial proteins for the lysosomal diges-
tion system, such as hydrolases or membrane-attached trans-
port proteins, into the degradation pathway.[147]
The formation of the so-called intraluminal vesicles begins 
already in EE.[148] This vesicle formation is driven by the 
endosomal sorting complex required for transport (ESCRT). 
A machinery consisting of four main proteins (ESCRT 0–III) 
and other associated proteins sorts membrane-bound pro-
teins according to their ubiquitination state.[148,149] It has been 
shown that only a minor fraction of the uptaken cargo can 
be excreted again into the extracellular space via slow/fast 
recycling endosomes and by this bypassing the possible 
lysosomal degradation.[150]
During the whole endosomal maturation process, the trans-
port of vesicles between the endosome and the TGN is very 
important as it promotes the maturation by removal of endo-
somal components while delivering lysosomal parts into the 
vesicle. Additionally, the vesicles initially formed at the cell 
membrane travel to the perinuclear area along the microtu-
bule (MT) network (MN) propelled mainly by a dynein-driven 
translocation. This translocation can be observed by live cell 
imaging, by tracking particles that colocalize with endosomes 
along the microtubular network.[151–153]
While the exact process of LE formation is not yet clearly 
understood, it is clear that LEs have very little in common with 
EEs. The dominant marker Rab5 is exchanged by Rab7 and the 
internal pH is decreased to around 5–6, which is achieved by 
proton pumps that influx H+ ions into the vesicle against the 
concentration gradient by hydrolyzing adenosine triphosphate 
(ATP).[154] During this maturation the LEs fuse with each other 
to form larger structures and finally combine with preexisting 
lysosomes to form the so-called endolysosomes. After this 
final fusion, the majority of the endosomal components are 
degraded and the lysosomal parts are preserved.[155] This pres-
ervation is achieved by protecting the lysosomal-facing mem-
brane part from degradation by excessive glycosylation.[156,157] 
This results in lysosomes being able to then be specifically 
marked using antibodies against lysosomal-associated mem-
brane proteins.[158] The fusion of endosomes with lysosomes is 
essential as the transport of freshly produced lysosomal compo-
nents to lysosomes is only achieved during this fusion and for 
a few subsequent minutes, as transports between the TGN and 
mature lysosomes have never been observed.[157,159] The whole 
process of endosomal maturation is summarized in Figure 2.
The reviews of Huotari and Helenius and Hu et al., respec-
tively, contain more detailed descriptions of endosomal matura-
tion and the endosomal–lysosomal system.[159,160]
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4.3. Degradation of Nanomaterials in Lysosomes
The degradation of nanomaterials inside the cells can mainly 
be attributed to the harsh environment found in the lys-
osomes.[161–164] Inside the lysosomal compartment, nano-
materials are exposed to an acidic pH (between 4.5 and 5), 
high ionic strength, and up to 50 different degrading enzymes. 
These acid hydrolases can degrade biomolecules such as 
DNA, RNA, proteins, lipids, and polysaccharides.[154,165,166]
Proteases, for example, cathepsin L, an unspecific protease 
that cleaves up to a third of the entire human proteome, 
have been identified to degrade the protein corona that can 
be attached to the nanomaterial surface as well as peptides 
conjugated onto the surface of AuNPs.[167,168] Wang et al. 
showed that human brain astrocytoma cells were protected 
from the toxic effects of cationic NPs by this protein corona. 
Only when the corona was degraded in the lysosomes did 
the NPs induce a loss of lysosomal integrity, followed by a 
release of lysosomal components into the cytoplasm leading 
to a cathepsin-induced apoptosis. Ma et al.[169] showed that 
the degradation speed of the protein corona is dependent on 
the corona composition. The authors compared the effects 
of AuNPs coated with either human serum albumin, human 
γ-globulin, or human serum fibrinogen on cell viability. 
They reported that the same particles with different corona 
provoke different biological responses, suggesting that both 
the speed and the cytotoxic effect can vary when different 
protein corona are present.
It has also been reported that enzymes in the lysosomes can 
dissolve the polymer coatings often used to stabilize the nano-
materials and/or to add a specific functional surface. This phe-
nomenon has been shown by Kreyling et al. in 2015, who used 
radiolabeled AuNPs coated with a radiolabeled indium polymer 
shell.[170] They showed in vitro that the particles ended up in 
endosomes and lysosomes after endocytosis. There, a separa-
tion between the inorganic gold core and the organic polymer 
coating was observed. In an in vivo study they showed that the 
particles accumulated in the liver, where they were endocytosed 
and processed in the lysosomes of liver cells. Subsequently, 
parts of the digested polymer shell were exocytosed, then 
filtered by the renal system, and finally excreted via the urine.
In addition to the digestion of protein coronas or surface 
modifications of nanomaterials in lysosomes, the dissolution 
of metal oxide NPs has also been shown.[171,172] In 2015 Jiang 
et al. published a report showing a time-dependent dissolution of 
AgNPs, subsequent to their endocytosis into epithelial cells.[173] 
The authors compared the Ag particle/Ag ion ratio in media 
at pH 4.5, simulating the environment inside lysosomes, and 
the media at pH 7, to the ratio of AgNPs and Ag ions found in 
the cell cytoplasm. They reported that the major fraction of the 
particle dissolution was probably caused by enzymes. This con-
jecture was based on the fact that only 7.5% of the total Ag was 
dissolved into ions when incubated in acidified media, in contrast 
to the dissolution of up to 80% of the total Ag after endocytosis by 
epithelial cells. Similar effects were also observed for other metal-
containing NPs such as Zn, Fe, and Au NPs.[174]
Figure 2. Endosomal maturation: After endocytosis, the endosomes travel along the microtubule (MT) network to the inner part of the cell. 
The constant exchange of cargo and membrane components with the trans-Golgi network provides the essential proteins for the endosomal maturation. 
In the end, the late endosome fuses with a lysosome to form an endolysosome, which delivers essential lysosomal components to the lysosome. 
Reproduced with permission.[159] Copyright 2011, John Wiley & Sons.
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In contrast, a number of other nanomaterials, such as 
mesoporous silica NPs, have been found to be degraded in 
a phosphate buffered saline (PBS) solution in the absence of 
degrading enzymes.[175,176] The composition of the degradation 
media (pH, flow, protein content, etc.) plays a crucial role in the 
degradation kinetics of any nanomaterial.[177] Additionally, the 
properties of the nanomaterials themselves, such as porosity 
and surface oxidation, have a great impact on their degrada-
tion speed. An in-depth discussion of silicon-based particles is 
included in the review of Croissant et al.[177] The clearance of 
silicon nanomaterials is addressed in Section 7.5 of this review.
4.4. Exocytosis
While endocytosis of nanomaterials has been intensively inves-
tigated in recent years, there are only a limited number of 
reports showing exocytosis of nanomaterials. Two pathways of 
exocytosis have been described, one constitutive and one that 
is regulated.[157,178] Constitutive exocytosis is observed in all 
cell types. Proteins are secreted by being packaged into trans-
port vesicles in the Golgi apparatus and then transported to—
and incorporated into—the plasma membrane. The regulated 
pathway is found in cells that are specialized for secreting their 
products, such as hormones, neurotransmitters, or digestive 
enzymes. This process is performed rapidly and on demand, 
which is often triggered by an influx of Ca2+ ions. To study 
exocytosis, it is possible to incubate cells at 4 °C or to expose 
them to different chemical inhibitors such as sodium azide or 
drugs that inhibit lysosomal exocytosis.[174,179,180] There may 
also be an eventual loss of the total nanomaterial load per cell 
as a result of mitotic division, nanomaterial exocytosis, and/or 
transcytosis (for reviews see refs. [132,181,182]).
It has been shown that endocytosis and exocytosis are 
coupled, and can stimulate or compensate for each other.[179] 
Furthermore, endocytotic processes occur much faster than 
exocytotic routes, where the excretion rate even decreases with 
increasing particle size, as shown for 14, 50, and 74 nm AuNPs 
in HeLa cells.[183] It is also known that many parameters, such 
as the cell type,[184] nanomaterial properties (i.e., size, surface, 
and shape), and their applied concentration and exposure time, 
can affect exocytosis significantly (for a review see ref. [185]). 
Since the nanomaterial surface can change during uptake and 
lysosomal processing, the exocytosed NPs may also exhibit a 
different surface and therefore recognize different targets or 
receptors on the cellular surface.[185,186]
5. Biodistribution and Biokinetics
The activity of any nanomaterial at the tissue or cellular level 
is dependent on the rate and extent of the material absorption, 
distribution, metabolism, and elimination (ADME) (Figure 3). 
In nanoscience, these processes are referred to as biokinetics, 
i.e., uptake, biodistribution, and elimination.[187,377]
The physicochemical properties of nanomaterials can differ 
quite a lot from their bulk materials as they inherit a vastly 
different volume-to-surface ratio.[188] These differences not 
only affect the biodistribution but also the biodegradation 
rates observed in vivo. For soluble nanomaterials, the degra-
dation products, mostly ions, share the same fate as their cor-
responding chemical solutes.[189–191] This leads to a systemic 
distribution, but also includes local retention in tissues or cells. 
In brief, the biodistribution of nanomaterials is controlled by 
many factors, such as size, surface properties, and dissolution 
rate of the nanomaterial, as well as tissue- or organ-dependent 
Figure 3. The biokinetics of nanomaterials: ADME stands for admini-
stration, distribution, metabolism, and elimination, and describes the 
common path all drugs follow when administered. A detailed under-
standing of the ADME is important to bring new medicines in the market. 
Reproduced with permission.[377] Copyright 2012, Elsevier.
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factors such as permeability or barrier tightness.[192–194] In gen-
eral, after inhalation, oral exposure, or intravenous injection, 
nanomaterials can be found in the liver, spleen, kidneys, bone 
marrow, the central nervous system (CNS), and local and sys-
temic lymph nodes.[162,194–196] Therefore, studies focusing on 
the biokinetics of nanomaterials should include these organs in 
their screening, in addition to their specific targeted organs.[186] 
To perform an accurate dosimetric risk extrapolation, it is nec-
essary to accurately correlate the effects to the retained drug 
dosage.[197,198] The guidelines for designing and testing new 
materials or drug delivery systems should include retention 
kinetics in the targeted organs or tissues as well as the adverse or 
beneficial effects observed there.
The effect of the different protein coronas that form in 
primary or secondary organs, which has been reported by 
various in vitro studies, is yet to be confirmed by appropriate 
in vivo studies.[169] The lack of such studies makes it diffi-
cult to evaluate the effects of the different corona on particle 
distribution or cell interactions as in vitro data often fail to 
accurately foresee in vivo results.[199,200]
The systemic biokinetics of a nanomaterial depends not 
only on the physicochemical properties of the nanomaterials 
but also on their biodurability/biodissolution and the point of 
entry. Biodurability has been defined as the tendency to resist 
dissolution and biotransformation within biological and envi-
ronmental media, which in turn may lead to bioaccumulation 
of nanomaterials.[189,201] Thus, this definition of biodurability 
essentially measures the dissolution rate of nanomaterials in all 
types of media and physiologically relevant solutions such as 
lysosomal fluid.
The route of exposure is also an important factor. The biokinetics 
and biodistribution of nanomaterials following intravenous 
exposure is different from the biokinetics/biodistribution of 
nanomaterials administered to the respiratory tract as described 
earlier.[101,202,203] In addition, a very recent series of three 
publications by Kreyling et al. showed that the biokinetics of 
intravenously injected nanomaterials does not represent a sur-
rogate biokinetic approach for pulmonary or oral routes of 
exposure.[204–206] The authors employed 70 nm radiolabeled 
TiO2 NPs containing 48V in rats to study the biokinetics and 
biodistribution in various tissues over the period of 1 h to 28 d. 
After intravenous injection, the highest titanium accumulation 
was found in the liver, followed by the spleen, carcass, skeleton, 
and blood after 1 h, after which the blood content decreased 
rapidly, while the distribution in the other organs and tissues 
remained constant until day 28. After oral administration, the 
predominant fraction was cleared via fecal excretion, whereas 
0.6% of the administered dose translocated across the GI tract 
and was finally found in liver, lung, kidney, brain, spleen, 
uterus, and skeleton. The exposure via intratracheal instillation 
resulted in a 4% translocation rate of the initial administered 
dose after 1 h and was retained mainly in the carcass, and this 
percentage decreased to 0.3% after 28 d. The organ fractions in 
the liver and kidneys remained constant. The clearance from 
the lungs via the larynx increased from 5% to 20% for all trans-
located/absorbed particles.
Physiologically based pharmacokinetic (PBPK) models have 
been developed that can accurately predict such relationships, 
and most of these models describe the fate of intravenously 
injected nondegradable nanomaterials.[207,208] It has been shown 
that the most important factors are the physicochemical prop-
erties of the nanomaterials (e.g., size and shape), blood/tissue 
coefficients of permeability, as well as the phagocytotic uptake 
by macrophages.[209] For the lung, a novel two-step approach to 
assess the biokinetics of inhaled nanomaterials has recently been 
presented. For this purpose, the translocation kinetics of aero-
solized gold nanoparticles across the epithelial tissue barrier was 
assessed in vitro, and then in a second step the distribution to 
secondary organs was predicted with a PBPK model.[210]
6. Mode of Clearance
Nanomaterials entering the vascular system can interact 
with cells from the blood circulation but will most probably 
be further distributed to peripheral organs. The distribution 
to peripheral organs, and especially their clearance, is highly 
dependent on their physicochemical properties, particularly 
their size and surface structure/modifications. Understanding 
the biodistribution and possible subsequent clearance from the 
body is of paramount importance for their further appli-
cation. However, nanomaterials that are not efficiently cleared 
from the body have a higher probability of interacting with 
cells, tissues, and organs and accumulating in the body due to 
their prolonged circulation time. Clearance of nanomaterials 
from the body can happen via different pathways. Renal clear-
ance is the most effective excretion, but due to the related size 
restrictions (6–8 nm) many nanomaterials cannot be efficiently 
cleared via this route and undergo biliary excretion where nano-
materials are processed by the liver and become excreted via the 
GI. Mucociliary clearance in the upper airways can be closely 
correlated with GI clearance, as nanomaterials trapped in the 
mucus are typically transported to the pharynx and then swal-
lowed. While clearance via the kidneys and liver can occur over 
a timescale from 30 min to a few days, nanomaterials that have 
been internalized by mononuclear macrophages can persist 
for a long time, trapped within the RES. The following section 
provides a brief overview of the potential clearance pathways 
(from the fastest, i.e., renal to the potentially slowest, i.e., RES) 
and considerations relevant to nanomaterial excretion. An over-
view of the clearance organs is found in Figure 4.
6.1. Renal Clearance
The kidneys are involved in a number of crucial physiological 
functions, such as the regulation of blood (ionic concentra-
tion, pH, volume, pressure, and osmolarity), production of hor-
mones, and the excretion of foreign substances and waste.[211,378] 
Following administration and their entrance to the vascular cir-
culation, nanomaterials can be efficiently excreted through the 
kidneys along with the urine. This form of clearance strongly 
depends on the size of the materials. Renal clearance is favorable 
as it requires minimal interaction and metabolism within the 
body, which reduces possible toxic effects.[212] Although ben-
eficial from a toxicological aspect, renal clearance significantly 
limits the circulation time of nanomaterials, which can have 
an impact on their efficacy. The excretion of substances and 
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production of urine is performed by three basic processes of the 
nephrons and collecting ducts—glomerular filtration, tubular 
reabsorption, and tubular secretion. Nephrons are the functional 
units of kidneys, built up by renal corpuscle and tubules, where 
blood plasma is filtered and the filtered fluid passes through. 
The renal corpuscle consists of the glomerulus, i.e., capillary net-
work, and the glomerular capsule, i.e., the double-walled epithe-
lial cup that surrounds the glomerular capillaries. Glomerular 
capillaries have a high surface area and are completely encircled 
with podocytes. Their particular anatomy allows formation of 
a “leaky” barrier that is up to 50 times more permeable than 
in other tissues and can act as a filtration membrane.[211,213,214] 
Substances filtered from the blood pass through the glomerular 
endothelial cell membrane, basal lamina, and the filtration slit 
formed by podocytes. At the level of the glomerular endothelial 
cell, the membrane is porous, with size limitations of ≈70–100 nm, 
which prevents filtration of blood cells. At the level of the basal 
lamina, proteoglycans prevent filtration of larger proteins, while 
podocyte expansions, i.e., pedicels, form filtration slits and slit 
membranes with a cutoff of 6–7 nm.[211] A schematic of the 
renal filtering system is depicted in Figure 5. Due to the slit 
membrane limitations, filtration of nanomaterials and renal 
clearance is strongly dependent on the particle’s hydrodynamic 
size. It has been shown that nanomaterials larger than 8 nm 
cannot be cleared and renal clearance is limited to nanomate-
rials smaller than 6 nm.[213–215] Filtration of intermediate-sized 
nanomaterials, i.e., between 6 and 8 nm, is dependent on the 
nanomaterial surface and the surface charge.[22] For QDs, it has 
been shown that the diameter should be less than 5.5 nm for 
efficient renal clearance.[22] The nanomaterials tend to interact 
with proteins in the blood, forming a protein corona, which 
leads to an increased hydrodynamic diameter that can have an 
impact on the clearance. Furthermore, the fate of the nanoma-
terials can also depend on the interactions of charged materials 
within the nephron during filtration.[213] Studies have shown 
that anionic NPs are filtered less successfully than neutral NPs, 
and even less than cationic ones.[22,213,214,216,217]
As previously mentioned, aside from renal filtration and 
secretion, one of the basic renal functions is renal reabsorp-
tion. During this process, most of the filtered ions, and small 
molecules such as glucose and amino acids, are reabsorbed 
by epithelial cells of the proximal tubules via specialized path-
ways, while most of the peptides and proteins are reabsorbed 
via pinocytosis.[211] Resorption of nanomaterials on the level 
of proximal tubules is still poorly understood or incompletely 
investigated, and the available data are inconclusive. It should 
also be noted that several studies exist showing that silica NPs 
with sizes significantly larger than 8 nm can be cleared via the 
urine.[218–220] The mechanism is far from fully understood, 
but a plausible hypothesis suggests that excretion of NPs can 
occur at the level of the proximal tubules.[221]
6.2. Hepatic Clearance
After the skin, the liver is the largest human organ and 
performs a range of functions. It is involved in macromolecule 
metabolism, storage, production, and conversion of molecules 
into waste products that can be excreted via the kidneys and 
Figure 4. Biodistribution of nanomaterials: following administration, 
nanomaterials can either interact with the primary tissue barriers and 
translocate into the blood circulation, or be directly injected into the 
blood from where they can be distributed to peripheral organs. Upon 
distribution, depending on their properties, nanomaterials can undergo 
renal (through kidneys, purple), hepatic (through liver, red), mucociliary 
(through lungs, blue), and gastric clearance (though GI, yellow), or reside 
within reticuloendothelial system (green).
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the intestinal tract.[211,379] Hepatic clearance represents the pre-
dominant route for the excretion of nanomaterials that cannot 
be cleared via the kidneys. The liver consists of two lobes 
separated by the middle hepatic vein. Blood is delivered to the 
liver via the hepatic artery and the portal vein. The portal vein 
further delivers blood from the spleen, pancreas, and intestines, 
while blood is drained via the left, middle, and right veins. This 
organ consists of specialized epithelial cells, i.e., hepatocytes, 
phagocytic Kupffer cells, resident immune cells, as well as addi-
tional specialized endothelial and epithelial cells (see Figure 6). 
The hepatocytes are the key cells of relevance to the clearance 
of nanomaterials. These cells excrete nanomaterials into the 
small intestine via the bile, after endocytosis and enzymatic 
breakdown.[222] As for the clearance via the kidneys, hepatic 
clearance is likewise highly influenced by the physicochemical 
properties of the nanomaterial, i.e., its size, shape, and surface 
charge.[215,223] Upon entrance to the liver via the blood 
circulation, nanomaterials can also be internalized by the 
Kupffer cells, which are specialized macrophages in the liver. 
Kupffer cells can internalize nanomaterials up to several 
hundreds of nanometers in size by phagocytosis or other 
endocytotic uptake mechanisms.[219,224] Nanomaterials 
smaller than 200 nm can either pass through or undergo 
transcytosis in order to interact with abovementioned hepat-
ocytes.[225,226] The impact of the surface charge upon cellular 
uptake has also been postulated. Kupffer cells are efficient in 
Figure 5. Renal ﬁlter system: renal ﬁltration and clearance are performed by the glomerular ﬁltration. The glomerulus is the capillary network, and 
the glomerular capsule is the double-walled epithelial cup that surrounds the glomerular capillaries. Glomerular capillaries are completely encircled 
with podocytes, which form a ﬁltration membrane. Substances that are ﬁltered pass through the glomerular endothelial cell membrane, basal lamina, 
and the ﬁltration slit formed by podocytes. Reproduced with permission.[378] Copyright 2005, The American Physiological Society.
Figure 6. Hepatic ﬁlter system: the liver consists of two lobes, separated by the central hepatic vein, while the blood is delivered to the liver via the 
hepatic artery and the portal vein. The liver consists of specialized epithelial cells, i.e., hepatocytes, phagocytotic Kupffer cells, resident immune 
cells (B cells and T cells), as well as additional specialized endothelial and epithelial cells. Reproduced with permission.[379] Copyright 2016, 
Nature Publishing Group.
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the internalization of anionic NPs, while hepatocytes have a 
preference for cationic NPs.[226–229] In general, Kupffer cells 
are more efficient in nanomaterial removal than hepatocytes; 
however, it should be noted that only nanomaterials pro-
cessed via hepatocytes can be cleared through the bile and 
gastrointestinal tract, while NPs captured by Kupffer cells 
remain in the RES.[230]
6.3. Mucociliary Clearance
As mentioned above, one of the potential exposure scenarios 
for nanomaterials is inhalation. The further fate of the nano-
materials and clearance depends on the lung compartment in 
which they have been deposited. The deposition of nanomate-
rials is size dependent. Larger materials (1–10 μm) are prefer-
entially deposited in the conducting airways (i.e., trachea and 
bronchi) with ciliated epithelial cells, whereas smaller mate-
rials (i.e., nanomaterials (<100 nm)) are localized in more 
peripheral lung regions (i.e., alveoli).[35] The first line of defense 
from inhaled materials and the fastest route of clearance is 
mucociliary transport, whereas penetration into the bronchial 
conducting pathways and lung periphery epithelium is a 
slower process.[231]
Mucus is secreted by airway epithelial goblet cells and sub-
mucosal glands. The mucus is formed by a two-layer mucus 
blanket over the ciliated epithelium, i.e., a low-viscosity sol 
layer, covered by a high-viscosity gel layer. Insoluble materials 
are trapped in the gel layer and are moved toward the pharynx 
(and ultimately to the GI) by the upward movement of mucus 
generated by metachronous beating of the cilia. The mucus 
blanket consists of a surfactant as an outermost layer, mucus, 
and the proximal periciliary layer. This periciliary layer has a 
less dense structure and, as proposed in 2012 by Button et al., 
a very distinct brush structure that enables penetration into 
the mucin layer and hence efficient beating of the cilia.[232] 
The conducting airways are lined by epithelial cells covered with 
numerous cilia at their apical side, which are ≈6 μm long 
with a diameter of 250 nm.[233] Cilia have microtubulae struc-
tures and their movement is generated by ATPases.[234] The 
metachronous ciliar beating moves the mucus to the pharynx 
together with particulate matter trapped inside it.[235] Mucus 
activity is dependent on the number of ciliated cells and their 
beating frequency, which can be 10–20 mm min−1 in tra-
chea.[236] Mucociliary clearance via the pharynx is the most 
common clearance route for nanomaterials deposited on the 
upper airway surface and was first described by Kilburn in 
1968.[235] Mucin with trapped materials will be directed to the 
pharynx via ciliar beating and can also be stimulated addi-
tionally via coughing, if cililar beating is insufficient.[237–239] 
The efficiency of the translocation of nanomaterials through 
pulmonary mucus is not yet fully understood, but it has been 
shown that nanomaterial mobility in the mucus is dependent 
on the adhesive or inert properties of the material, as well as 
on its size.[240,241]
The clearance kinetics in the lung periphery is much slower 
due to the absence of mucociliary action. The nanomate-
rials either can be eliminated by: (i) phagocytosis and subse-
quent transport by macrophages, (ii) by alveolar epithelium 
translocation into the blood circulation, or (iii) sequestration by 
dendritic cells and transportation to the draining lymph nodes.[40]
6.4. Gastrointestinal Clearance
When nanomaterials are either ingested or inhaled, and then 
cleared via mucociliar clearance, they pass from the mouth 
into the laryngopharynx. The laryngopharynx continues into 
the esophagus, which delivers swallowed nanomaterials to the 
stomach. The stomach connects the esophagus with the duo-
denum, which is the first part of the small intestine.[211] One of 
the main functions of the stomach is to digest, mix, and store 
the food until the duodenum is ready for the next digestion 
steps. Due to its role in digestion, the surface of the stomach is 
quite complex as it has to provide acids and enzymes for diges-
tion, but at the same time has to protect itself from digestion. 
For that reason, the surface of the stomach is organized into 
gastric pits made of surface mucous cells and mucous neck 
cells secreting mucus, parietal cells secreting hydrochloric acid 
and intrinsic factor, chef cells secreting pepsinogen and lipase, 
and finally hormone-producing G cells secreting gastrin.[211] 
In summary, the stomach secretes gastric juice (mainly 
aqueous HCl), which can induce protein denaturation. This 
is performed by pepsin, which starts the digestion of proteins, 
and gastric lipase, which assists in the digestion of triglycerides. 
The stability and integrity of nanomaterials in the stomach is 
strongly dependent on their chemical structure. Nanomaterials 
consisting of proteins, lipids, and acid-sensitive material will 
already be degraded at this step of the clearance process.
The small intestine has a specially adapted structure for the 
digestion and absorption of nutrients. Even though the intes-
tine is highly efficient in absorption and digestion due to its 
length (≈3 m), its performance is additionally increased and 
optimized by the formation of folds, villi, and microvilli struc-
tures that significantly increase the surface area. As previ-
ously mentioned, nanomaterials that have been internalized 
by hepatocytes are typically excreted via bile to the intestines, 
and can either be translocated across the intestinal barrier or 
excreted from the body via feces.[230]
6.5. The Reticuloendothelial System
The term RES is used to describe the group of phagocytic cells, 
i.e., monocytes, macrophages, dendritic cells, and neutrophils, 
which form a network or a reticulum in different organs, 
whereas “endothelial” refers to their proximity to the vascular 
endothelium.[242] One of the main functions of this system is 
the sequestration and clearance of materials found in the blood 
and lymph nodes.[211] The RES predominantly spreads across 
the liver and spleen, although cells of the RES can be found in 
all major organs. The liver is considered to be the major part 
of the RES and its residing macrophages, i.e., Kupffer cells, 
are crucial for RES function.[211] It is interesting to note that 
Kupffer cells were isolated by Rous in 1933 by injecting mag-
netic particles intravenously and following the phagocytosis by 
Kupffer cells.[242,243] Cells belonging to the RES are also found 
in the lungs, where airway and alveolar macrophages perform 
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phagocytosis of inhaled foreign materials.[40,211] The existence 
of microglia cells in the brain is also an indicator of how vital 
the cells of the RES are for the function of all organs. These 
cells have been shown to be able to both phagocytose and 
migrate,[242,244] although they do not often come in contact with 
particles due to the tight BBB. In general, tissue-resident mac-
rophages originate from precursors that arise during embry-
onic development and are maintained through self-renewal, 
independent of adult hematopoiesis. However, during inflam-
matory response, blood monocytes may enter the tissue and 
differentiate into monocyte-derived macrophages.[245] In general, 
nanomaterials can be removed by the macrophages, which 
function as sentinels at all epithelial tissue barriers in the 
human body. Nanomaterials with a protein corona on their sur-
face, and more specifically those tagged for opsonization, are 
prone to this type of clearance.[246] Once they are in phagocytes, 
nanomaterials will be processed and degraded in the lysosomes 
when possible. Chemically inert nanomaterials will remain 
in intracellular compartments until sequestered at the level 
of the spleen and liver, making their clearance significantly 
slower.[215,223,247,248] Even the death of the cells does not neces-
sarily mean that the nanomaterials will be cleared because the 
cell debris (including the nanomaterials) can be collected and 
taken up by other phagocytes, resulting in chronic persistence. 
In general, dead cells are promptly recognized and cleared after 
efficient signaling, which includes signals by which phagocytes 
are attracted and stimulated to engulf dead cells. Dead cells 
engulfed by phagocytes are then digested.[249,250]
The RES is usually closely correlated with the long-term fate 
of nanomaterials in an organism, as nanomaterials captured 
by these cells persist for a long time in RES organs, especially 
if nanomaterials do not undergo degradation in the lysosomes 
and/or exocytosis.
The surface charge and hydrophobicity of nanomaterials 
also represent a key feature for overcoming rapid clearance and 
prolonging circulation lifetime, which is often desired for drug 
delivery systems. The overall interactions of nanomaterials with 
biomolecules are highly dependent on the size and the surface 
of nanomaterials, as previously demonstrated in several studies 
by Dawson and co-workers.[76,77,82] Nanomaterials with positively 
charged surfaces show high binding affinity to negatively charged 
molecules found in the blood, such as serum proteins and sugar 
moieties from cell membranes. In contrast, neutral and nega-
tively charged particles show reduced binding to serum proteins, 
leading to prolonged circulation time.[251] It has been shown that 
surface modifications using the synthetic polymer polyethylene-
glycol (PEG) and “self” peptide CD47 induce a reduction of the 
clearance by the RES, resulting in an increase in blood circu-
lation time and better pharmacokinetic properties.[252,253]
7. Long-Term Fate of Clinically Relevant 
(Bioinspired) Nanomaterials
For the design and optimization of biomedical nanomaterials it 
is not only important to address their efficacy in vivo, but also 
to investigate their fate and possible clearance. In particular, the 
long-term fate of nanomaterials that are biopersistent and can 
stay longer in the human body, i.e., from weeks to years, has to 
be considered. In vitro experiments might be applied to obtain 
an initial mechanistic insight into uptake, possible degradation 
and/or release at the cellular or tissue level. However, to under-
stand the long-term biokinetics, in vivo experiments are needed.
7.1. Liposomes
Liposomes are probably the most commonly used nanoma-
terials for drug delivery. These are bioinspired vesicles con-
sisting of a phospholipid membrane structure mimicking the 
cell membrane, and are one the most frequently applied drug 
delivery systems due to their biodegradability, low immuno-
genicity, and toxicity. These vesicles allow the loading of var-
ious soluble drugs into the hydrophilic, aqueous center, the 
lipophilic membrane, or the interface between.[254] Being able 
to incorporate drugs into the liposomes provides the advan-
tage of protecting the active compound from degradation and 
increases the half-life in the body. A large amount of research 
has been conducted on this topic since the first description of 
liposomes in the 1980s.
The first generation of liposomes had short in vivo half-lives, 
being cleared very quickly. In 1985, Scherphof et al. showed that 
the RES rapidly cleared the intravenously injected liposomes 
out of the body.[255] This finding helped to develop drug formu-
lations to target diseases affecting the RES, such as microbial 
or parasitic infections.[256–258] While the RES does not recognize 
the liposomes themselves, a number of groups showed that the 
attachment of certain serum proteins, the so-called opsonins, 
is the major factor that leads to the rapid clearance of the 
liposomes.[259–263] In contrast to opsonins, dysopsonins have 
also been identified that help to prevent the phagocytosis and 
thus increase the liposomal half-life. Furthermore, the comple-
ment system is another line of defense the body possesses 
against liposomes. Most important here is the assembly of the 
membrane attack complex, which forms lytic pores that lead to 
the release of the liposomal content.[264]
In order to avoid the fast clearance of the liposomes by the 
RES, other approaches have also been attempted. The first idea 
was to modulate the size and surface charge. It was found that 
larger liposomes, such as multilamellar liposomes (MLV) with 
sizes of around 500–5000 nm, are cleared faster than the smaller 
single lamellar liposomes (SLV).[265,266] In addition to the size, 
the charge of the liposomes also influences their fate in the 
body. Negatively charged liposomes are cleared more rapidly 
from the blood than their neutral counterparts, while positively 
charged liposomes appear to be toxic and are cleared from the 
body even faster.[267–269] Another method proposed to overcome 
the fast clearance is to expose the body to empty liposomes 
prior to the application of the drug-containing derivatives. 
This would lead to the saturation of the RES and thus longer 
circulation times for the drug-containing liposomes.[192,270]
Second-generation liposomes were then developed by the 
modification of surface properties, by adding coatings of gly-
colipids, sialic acid, or PEG around the membrane.[271,272] 
These surface modifications substantially increased the half-
life of liposomes and enabled the use of these drug delivery 
systems for new applications since long-circulating liposomes 
could profit from the EPR and accumulate in tumors or sites of 
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inflammation.[273] In particular, PEG has already received much 
attention for its beneficial effects combined with drugs or nano-
carrier systems, such as increasing stability and solubility, or 
decreasing toxicity and antigenicity.[274,275] As PEG is a synthetic 
polymer, the molecular weight and its structure can be modi-
fied to fit individual needs. The increased circulation time due 
to the reduced uptake in the RES is attributed to the reduced 
interaction of PEG with serum proteins, which is presumably 
due to steric hindrance.[276,277] In 1991, Allen et al. showed 
that the length or molecular weight of the PEG, and the den-
sity of the PEG packing onto the liposomal surface, influence 
this stealth effect. In general, longer PEG chains and denser 
packing lead to longer blood circulation times.[271] Together 
with the EPR effect, PEGylated liposomes have now become 
a commonly used and accepted system for drug delivery, but 
there are still limitations one has to consider. For instance, the 
drug release needs to be controlled at the target site, as only 
the free, released drug is able to diffuse into the cells and there 
perform its action.[278,279] This also results in difficulties in 
quantification—the ratio of released drug to encapsulated drug 
determines the efficiency of the system, but the determination 
of this ratio is challenging.[280]
To overcome some of these problems, liposomes have been 
developed where the PEG coatings are detachable in acidic 
pH, an environment that has been found in close proximity to 
tumors, where they are subsequently taken up by the cancer 
cells.[281] Another approach was to conjugate targeting molecules 
on top of the PEG, instead of simply relying on passive targeting 
via the EPR effect. These targeting moieties could be specific 
antibodies, receptor ligands, or other biomolecules.[282–284]
Interestingly, Laverman et al. and Ishida and co-workers 
reported in 2001 and 2008, respectively, that PEGylated 
liposomes have altered pharmacokinetic behavior after an ini-
tial dose if the second dose is administered within a few days of 
the first dose. They report that the clearance of this second dose 
happens at a much faster rate than initially expected. This effect 
is called accelerated blood clearance and has been reported 
extensively in connection with PEG.[285–289] To overcome this 
issue, PEG has been under heavy investigations and also PEG 
alternatives were studied. A detailed review about this topic can 
be found in the review of Knop et al.[290]
While this review is focused on the long-term fate of the 
nanomaterials, there are few reported studies that investigate 
the biodistribution of the administered liposomes after more 
than one week. This is somewhat understandable for a number 
of reasons. First, the detection of liposomes in the body can 
be quite challenging, as they are vesicles where the composi-
tion barely differs from other membranes in the human body 
(if they are not labeled). When radiolabeled, for example with 
111In, which is commonly used for this purpose, then the 
question remains if the indium is still in or attached to the 
liposomes, or if the liposomes are degraded and the indium 
persists in the body.[279,291–293] Another problem is the fast clear-
ance of the liposomes out of the body, as mentioned above. 
While this is advantageous for some applications, it makes 
long-term studies of their biodistribution difficult to perform.
The biodistribution at early time points (up to 3 d postadmin-
istration) has been extensively studied. For radiolabeled (186Re) 
Doxil (liposomal-encapsulated doxorubicin), Soundararajan et al. 
found that 4 h after the intravenous administration to rats, the 
liposomes were found mainly in the spleen.[294] The distri bution 
was found to have changed after 48 h, where they began to be 
localized in the kidneys. However, the amount of liposomes 
in the spleen remained constant until 96 h postexposure. 
The liver seemed not to be a target. This is in contrast to the 
findings of Chang et al.,[295] who reported the biodistribution of 
PEGylated 188Re-BMEDA-liposomes in mice to show accumula-
tion in the liver over 72 h. Up to 4 h after the injection, the main 
load was still found in the blood. The distribution then shifts 
and most of the liposomes were found in the feces. The liver 
and the lungs immediately showed some accumulation, but the 
lung burden was cleared within 24 h, while the liver showed 
increased values over the whole 72 h period. The spleen began 
to accumulate the liposomes after 4 h, where it reached similar 
levels to the liver, while the kidneys showed immediate accumu-
lation, which decreased over the first 24 h. Chow et al. reported 
the comparison of 111In-labeled liposomes with either 0.9 or 
6 mol% PEG.[291] This study again demonstrated the influence of 
the PEG density on the biodistribution. The authors reported a 
much higher retention in the blood and accumulation in tumors 
when the mice were exposed to highly PEGylated liposomes. 
On the other hand, the accumulation in the spleen, liver, 
and kidneys was found to be significantly lower.
7.2. Micelles
Micelles are monolayers of aliphatic molecules, which means 
that classically they possess a hydrophobic core, in contrast to 
liposomes, which have hydrophilic cores. They offer the pos-
sibility of incorporating hydrophobic drugs that would not oth-
erwise be soluble under physiological conditions. Commonly 
used micelles are formed using either synthetic polymers (e.g., 
polypropylene) or bioinspired polymers like polysaccharides 
(e.g., cellulose, heparin, and dextran).[296,297]
Similar to the liposomes, micelles are quite difficult to detect 
in the body and require special labeling in order to do so. This 
has either been done by incorporating fluorescent dyes, metal 
particles, or radioactive labels.[298–300] However, the detection 
methods for the labels are indirect and after being adminis-
tered the micelles can potentially separate from their cargo, 
making the observed biodistribution questionable. These issues 
have led to a lack of long-term biodistribution data for micelles, 
as most studies only focus on the first few hours or days.
There are two main factors that influence the fate of micelles 
in vivo, namely their size and degree of PEGylation. In 2015, 
Wang et al. investigated these influences on the accumulation of 
micelles in tumors in mice.[300] Their findings, which are sum-
marized in Figure 7, show that the half-life of micelles increases 
with size and PEGylation degree, which they define as the mass 
fraction of the PEG moiety relative to the total block copolymer. 
However, the half-life, which is at most 15 h, still remains short. 
The biodistribution analysis in this study only included data 
from the liver, spleen, and kidneys after 24 h postinjection, sug-
gesting that the clearance is mainly performed by the liver and 
the spleen, while the kidneys are not significantly burdened.
Ebrahim Attia et al. presented biodistribution data of fluo-
rescently labeled, PEGylated diblock copolymeric micelles up 
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to 96 h postinjection in mice.[301] Their data suggest, in agree-
ment with Wang et al., that the main load of the micelles is 
cleared mostly by the liver, and to a lesser extent the spleen. 
In addition, an accumulation of the PEGylated particles in the 
tumor tissue was also observed. The kidneys showed only weak 
fluorescent signals and the heart and the lungs were both below 
the detection limit for the epifluorescence.
7.3. Gold Nanoparticles
Although not strictly bioinspired, gold nanoparticles or nano-
clusters are used extensively for medical applications, such as 
imaging, cancer irradiation therapy, or as drug delivery sys-
tems. Their inert properties also make them a reliable tool for 
biomedical studies.[302,380,381] However, the available data on 
acute toxic effects of these materials are frequently contradic-
tory, with in vitro studies variously reporting both cytotoxic 
effects and no impact.[303] The main conclusion that can be 
drawn from present in vitro data is that the measured toxicity 
strongly depends on the surface modification; however, the bio-
logical system, concentration, and application method also have 
to be considered.[304] Concerning in vivo toxicity, in 2009 a study 
was conducted comparing different sizes of noncoated AuNPs. 
It was found that at a dose of 8 mg kg−1 per week, particles with 
diameters of 3, 5, 50, and 100 nm did not have a toxic effect, 
while 8, 12, 17, and 37 nm sized NPs had severe effects on 
the mice’s health.[305] However, concerning the long-term fate 
of these particles, data are scarce. The studies covered in this 
review are summarized in Table 1. In a recent study carried out 
by Wang et al., the influence of the charge of ≈3.5 nm nano-
particles on retention in kidneys and accumulation in tumor 
tissue in mice was investigated over a period of 90 d. In all of 
the tested tissues except the kidneys, there was still a detectable 
amount of gold present regardless of the charge of the parti-
cles.[306] Those findings stand in contrast to a study published 
by Naz et al., who investigated AuNPs with sizes of 2, 5, and 
10 nm over 90 d and found a more complete elimination of all 
sizes in all tested organs.[307] The findings of these conflicting 
studies are summarized in Figure 8. With increasing size, the 
data become more concise: Fraga et al. used 16 nm AuNPs to 
study their long-term fate in rats.[308] The particles were coated 
with citrate or the pentapeptide CALNN (cysteine–alanine– 
leucine–asparagine–asparagine), forming a water-excluding layer 
on the NPs. The authors reported an elimination of gold from 
almost all tested organs (thymus, heart, lung, kidneys, brain, 
muscle tissue, small intestine, femur, testis, and blood), a 50% 
reduction in the liver and spleen, and persistence in the tail. 
Furthermore, another study investigated the fate of 20 nm 
AuNPs in rats over a period of two months. The highest rela-
tive levels of NPs were found in the liver, spleen, and kidneys. 
Other tested tissues, such as the blood, small intestine, tongue, 
adrenal gland, and testis, showed persistent AuNPs concentra-
tion, but to a lower relative degree, while the remaining samples 
(lung, heart, aorta, thymus, esophagus, stomach, cecum, 
colon, pancreas, bone tissue, muscle tissue, skin, olfactory 
bulb, frontal cortex, hippocampus, striatum, thalamus/hypo-
thalamus, brainstem, cerebellum, bladder, feces, and urine) 
Figure 7. Half-life and biodistribution of differently sized and PEGylated micelles: the a) half-life, b) area under curve (AUC), and c) biodistribution 
of micelles as a function of size and amounts of PEG. Larger micelles with high amounts of PEG stay longer in the circulation and are predominantly 
cleared by the spleen and the liver, whereas the kidneys are not heavily burdened. All of the experiments were carried out in mice. Reproduced with 
permission.[300] Copyright 2015, American Chemical Society.
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showed negligible concentration.[309] Finally, gold nanorods 
≈55 nm in length and 13 nm in width were tested over a period 
of 28 d in rats. In feces, bone tissue, muscle tissue, lung, heart, 
and brain, the gold concentration showed a decreasing trend 
(but was still detectable), while the concentrations inside the 
kidney, spleen, and liver either increased or were stable.[227] 
For 40 nm AuNPs, a more extensive study was conducted 
on mice, revealing similar results: substantial amounts of 
gold were found in the liver even after 180 d postinjection, 
supporting the claim that biological systems lack a suitable 
system for clearing the injected particles.[223] Similarly, Goel 
et al. tested CYT-6091, a prototypal nanomedicine consisting 
of a PEGylated colloidal gold core 27 nm in size, with TNF-α  
attached to the surface to target cells present in the tumor 
interstitium in mice, over 120 d.[310] This study supported the 
persistence of the NPs in the spleen, liver, and kidneys.[311] 
Finally, 110 nm Au-cored NPs with 10 nm silica shells were 
tracked in mice for up to 28 d. The measurable concentrations 
of gold in the spleen and liver at the endpoint were also in 
line with the above studies. In conclusion, the available data 
point toward a long persistence of AuNPs, especially above a 
certain threshold of size. Inversely, literature addressing 
AuNPs below that threshold suggests a rather complete 
(>70%) and fast clearance via the urine of the animal as it was 
observed exemplarily for the imaging agent Au@DTDTPA 
72 h postexposure by Alric et al.[307,312] Therefore, the further 
investigation of possible chronic implications, especially of 
AuNPs of greater size, is of utmost importance in order to 
safely promote the translation of AuNPs to clinical use.
7.4. SPIONs/Iron Oxide
Superparamagnetic iron oxide nanoparticles are currently being 
extensively investigated for a variety of applications. Because 
of their particular magnetic properties, they have already been 
approved as contrast agents in magnetic resonance imaging 
techniques, and they are also used for hyperthermia-based 
cancer treatment due to their ability to generate heat when 
exposed to an alternating magnetic field, as in the case of FDA-
approved NanoTherm.[313–315] Since SPIONS have already made 
their way into the clinic, their biological effects have already been 
extensively investigated, indicating no major signs of acute tox-
icity.[316,317] However, less effort has been put into understanding 
their long-term fate, but it has been shown that iron oxide can 
be recycled the same way as the iron oxide present as ferritin 
in hemoglobin.[318] Ferritin consists of an iron oxide core of 
≈8 nm and a surrounding protein shell that increases the hydro-
dynamic diameter up to 13 nm.[319] When red blood cells (RBCs) 
are aged or damaged they are taken up by macrophages, and 
the protein shell around the ferritin complex is rather quickly 
digested by enzymes present in lysosomes. Subsequently, the 
iron oxide core also dissolves readily in the acidic lysosome and 
can be reused in the bone marrow to make new RBCs.[318,319] 
It is thought that iron oxide nanoparticles, which end up in 
lysosomes, are dissolved and recycled similarly to ferritin.[319] 
For instance, Gazeau and co-workers followed iron oxide nano-
cubes in vivo for a maximum of 14 d by aberration-corrected high-
resolution transmission electron microscopy.[320] The authors 
found a stochastic corrosion process to be governing degradation 
Table 1. Long-term biodistribution data on gold-based nanomaterials.
Material Size [nm] Animal Investigated tissuea) Longest timepoint Reference
Ethanediamine-coated 
Au NPs
3.2 Mouse K, TT, Te, Li, L, H, S 90 d [306]
Ethanedioic-acid-coated 
Au NPs
3.7
Au NPs 2 ± 0.5 Mouse Li, S, L, H, K, Br 90 d [380]
5 ± 1
10 ± 2
CALNN-coated Au NPs 16 Rat Th, H, L, K, Br, M, SI, Fa, 
Te, Bl, Li, S, T
28 d [308]
Citrate-coated Au NPs
Au NPs 20 Rat Li, S, K, Bl, SI, To, AG, Te, 
L, H, A, Th, E, St, C, Co, 
P, Bo, M, Sk, OB, FC, Hi, 
Sa, Th, BT, Cb, Bd, Fa, U
2 months [309]
Au nanorods 55 × 13 Rat Fa, M, L, H, Br, K, S, Li 28 d [227]
Au NPs 40 Mouse Li 180 d [223]
CYT-6091 (PEGylated Au 
NPs containing TNF-α)
27 Mouse S, Li, K, L 120 d [311]
PEG stabilized silica 
coated Au NPs
110 Mouse Bl, Li, L, S, M, K, BT, Br 28 d [381]
a)E: esophagus; A: aorta; TT: tumor tissue; H: heart; L: lung; K: kidney; Br: brain; M: muscle; SI: small intestine; Te: testis; Bl: blood; Li: liver; S: spleen; T: tail; To: tongue; 
AG: adrenal gland; St: stomach; C: cecum; Co: colon; P: pancreas; Bo: bone; Sk: skin; OB: olfactory bulb; FC: frontal cortex; Hi: hippocampus; Sa: striatum; Th: thalamus; 
BT: brainstem; Cb: cerebellum; Bd: bladder; Fa: feces; U: urine; F: femur; and the bold letters indicate that the organ tested positive for nanoparticles.
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in vivo as well as in vitro, as well as an enrichment in iron-filled 
proteins close to lysosomes at day 14 postexposure, providing 
further evidence for the importance of the ferritin pathway for 
iron oxide NP long-term fate.[320] Taking this into account, the 
long-term biopersistance of SPIONs in cells or tissue is rather 
unlikely. Nevertheless, a couple of long-term studies were 
conducted (as summarized in Table 2): Briley-Saebø et al. 
investigated rat livers after injection of the commercially 
Figure 8. Gold nanoparticle biodistribution up to 90 d: graph plots showing results obtained by Naz et al. indicating a substantial clearance of 2, 5, 
and 10 nm Au NPs after 90 d measured by ICP-AES. The bar plots, on the other hand, depict the results obtained by Wang et al. with ICP-MS. Here, the 
authors did not observe a clearance independent from the charge of the roughly 3.5 nm Au NPs. Upper panel block (A–F): Adapted with permission.[380] 
Copyright 2016, Taylor & Francis. Lower panel block (bar charts): Adapted with permission.[306] Copyright 2016, DOVE Medical Press.
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available contrast agent Clariscan over a time frame of 133 d 
postinjection.[321] Even though the plasma half-life of the com-
pound was determined to 50 min at the highest administered 
concentration in pigs,[322] in the rat liver the study found longer 
half-lives by relaxometry, a technique to analyze magnetic 
particles.[321] In the same study, the concentration of Clariscan 
dropped below the detection limit of inductively coupled plasma 
atomic emission spectroscopy (ICP-AES) after 45 d, but could 
still be measured by relaxometry.[321] This indicates a lack of sen-
sitivity of ICP-based measurements when compared to relaxom-
etry. Furthermore, the study found a strong correlation between 
clearance time and administered dosage. This is in line with 
the work of Levy et al., which showed residual characteristic 
magnetization measured by ferromagnetic resonance and a 
superconducting quantum interference device after 90 d in 
mouse liver and spleen, indicating the presence of ferromag-
netic nanoparticles.[323] Recently, Keselman et al. used mag-
netic particle imaging (MPI) to study SPIONs over a period of 
70 d.[324] The authors found that the SPIONs were cleared out of 
the blood within hours and the liver and spleen showed SPION 
activity even after 70 d, as shown in Figure 9, indicating that 
SPIONs persist for a long time in the body.[324]
7.5. Silica
Amorphous SiO2 NPs, in particular mesoporous NPs, are inter-
esting materials for biomedical applications due to their porosity 
and high surface area, and hence high drug loading capacity. 
On the other hand, SiO2 NPs fall into the category of bioin-
spired materials, as silicon can be naturally found in the body, 
in particular in bone, cartilage, and supportive connective 
tissue. As such it can be used as a supplement or an adjuvant in 
drug preparation, and it has been approved by the FDA since it 
is generally regarded as safe. Amorphous silica has been used 
in drug delivery since 1983.[325] Thus far, the only type of silica 
that has gained approval for human clinical trials by the FDA is 
the Cornell dots (C-dots), while polysiloxane-based AGulX 
(activation and guiding of irradiation by X-rays) nanoparticles 
have entered clinical trials. AGulX is a magnetic resonance 
contrast agent based on gadolinium with a hydrodynamic diam-
eter of ≈3 nm and is used for radiosensitization and multimodal 
imaging. It has been showed in the mouse model that AGulX 
NP formulations allow efficient renal clearance and a mini-
mized NP localization outside of the kidneys (only 0.2% were 
detected). After four weeks, most of the NPs are excreted via the 
kidneys (0.5% of initial dose remains), and the NPs do not 
undergo degradation.[326] Although lanthanide-based NPs show 
great promise for their safe application in nanomedicine they 
will not be covered in this review as this subject has been 
Table 2. Long-term biodistribution data on iron-based nanomaterials.
Material Size [nm] Animal Investigated tissuea) Longest timepoint Reference
Clariscan (monocrystalline 
SPION)
5.6 ± 1.2 Rat Li 133 d [321]
P904 (glucose-derivative-
coated maghemite 
SPIONS)
8 Mouse Li, S 90 d [323]
Ferucarbotran (carboxy-
dextran-coated multicore 
magnetite SPION) LS-008 
(PEG-coated single-core 
magnetite SPIONS)
3–5 (26.3 ± 1.5) Rat Li, S, Bl, K, L, H 70 d [324]
a)H: heart; L: lung; K: kidney; Bl: blood; Li: liver; S: spleen; and bold letters indicate that the organ tested positive for nanoparticles.
Figure 9. Long-term clearance of SPIONS (Ferucarbotran and LS-008) 
tracked with MPI in rats: even after 70 d, a residual signal could be 
observed in the spleen and liver, indicating slow clearance for both. 
Furthermore, LS-008 shows predominant clearance by the spleen, and 
Ferucarbotran by the liver. Reproduced with permission.[324] Copyright 
2017, IOP Publishing.
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previously reviewed.[212,327,328] The particles consist of fluores-
cent molecules encapsulated in a silica core that is overcoated 
with a silica shell, further functionalized with polyethyleneg-
lycol. By attaching peptides that recognize receptors on cancer 
cells, this hybrid system is primarily used as a cancer diagnostic 
tool. The main challenges for efficient cancer targeting are the 
renal clearance and unspecific biodistribution. Due to the small 
size of C-dots (10 nm) and their specific functionalization 
(integrin targeting), the nanoparticles are efficiently cleared via 
the kidneys, and RES uptake has been minimized. C-dots (for-
mulation-124I cRGDY–PEG–C dots) have been monitored for 
their tissue distribution and clearance in humans using quanti-
tative PET imaging, which showed a half-life of 13–21 h mostly 
due to the fast clearance by the kidneys (90%). The remaining 
10% has been postulated to be cleared via hepatobiliary system, 
taking into account that all hepatic activity is ultimately excreted 
via the hepatobiliary route.[329] A previous mouse study from the 
same group showed that most of the C-dots (<10 nm) without a 
PEG coating ended up in the liver, whereas 124I-cRGDY–PEG–
C-dots were cleared by the urinary system.[330] Interestingly, 
C-dots did not show accumulation in the liver, spleen, lung, 
or bone marrow. These C-dots are currently the only silicon-
based nanomaterials approved to be used in humans; however, 
the long-term fate of the NPs and their biodistribution has so 
far only been studied in animal models, predominantly in mice 
and rats (as summarized in Table 3). He et al. investigated the 
effects of PEGylation and size on the in vivo biodistribution of 
mesoporous silica nanoparticles (see Figure 10). In this study, 
Table 3. Long-term biodistribution data on silicon-based nanomaterials.
Material Size [nm] Animal Investigateda) tissue Longest timepoint Reference
PEG mesoporous 
SiO2NPs; mesoporous 
SiO2NPs
80–390 Mouse and Rat S, Li, L, K, H 1 month [331]
14C-SiO2NPs 33 Mouse S, Li, L, K, CLN, BM, Br, 
M, Ad
8 weeks [221]
125I-SiO2NPs 20 Mouse Li, S, L, K, St, Bl, Br, In 30 d [333]
80
Rhodamine B SiO2NPs 50 Mouse K, Li, S, Fa, Br, L 4 weeks [332]
100
200
Mesoporous hollow 
SiO2NPs
110 Mouse S, Li, L, K, Br, Te 45 d [338]
SiO2NPs 110 Mouse Li, S, L, K, In, Fa, M 7 d [337]
Rod-like SiO2NPs-FITC 
and PEG
185 AR = 1.5
720 AR = 5
Mouse Li, S, L, Br, K, Bl 18 d [195]
Cationic mesoporous 
SiO2NPs
80 Mouse H, L, Li, S, K, St, In, P, 
Fa, Bd, Te
3 d [334]
C-dots 10 Human Pl, U, S, Thy, Pa, K, Li, L, 
M, Sp, Bd, Br, GI, H
3 d [329]
AGulX 3 nm Mouse Li, Bl, S, K 4 weeks [326]
125I-SiO2 115 AR = 1 Mouse L, Li, S, K 3 d [336]
120 AR = 1
139 AR = 7.6
ORMOSIL nanoparticle 20 Mouse In, Li, K, Sk 15 d [382]
SiO2NPs 20 Rat Br, K, Li, L, S, Te, Ov 14 d [339]
100
SiO2NPs 150 Rat K, L, H, Li 4 d [340]
SiO2NPs 20 Rat Pl 28 d [383]
100
SiO2NPs (3 different 
shapes)
85 AR = 1
175 AR = 5
Mouse Li, L, S, K, In 7 d [384]
a)H: heart; L: lung; K: kidney; Br: brain; M: muscle; Te: testis; Bl: blood; Li: liver; S: spleen; P: placenta; Fa: feces; St: stomach; Sk: skin; Bd: bladder; BM: bone marrow; 
Ad: adipose tissue; CLN: cervical lymph nodes; Ov: ovary; Pl: plasma; In: intestine; U: urine; Thy: thyroid; Pa: parotid; Sp: spine; GI: gastrointestinal tract; AR: aspect ratio; 
and bold letters indicate that the organ tested positive for nanoparticles.
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NPs of sizes 80–390 nm were injected into the tail vein of mice 
and rats. The biodistribution of the NPs was tracked over one 
month by taking advantage of their fluorescein isothiocyanate 
(FITC) functionalization. The particles were detected mostly in 
the spleen, liver, and in lower concentrations in the lungs, kid-
neys, and heart. The authors observed that the smallest ana-
lyzed nanoparticles (80 nm) showed the longest circulation 
time, especially for the PEGylated particles. While PEGylation 
hindered the sequestration of NPs and increased circulation 
time, increasing the size of the NPs had an opposite effect. 
Larger NPs showed faster degradation, possibly due to the fact 
that they were more efficiently captured within the RES. In gen-
eral, during the first month postadministration of larger parti-
cles (>80 nm), the amount of silica present in the liver decreased 
and silica degradation products were detected in the urine. 
Their biodistribution data are summarized in Figure 10.[331] 
Although this study provides extensive information on how size 
and PEGylation can play a role in the long-term fate of NPs, it 
should be noted that fluorescence-based measurements mainly 
provide semiquantitative information. Malfatti et al. used 
accelerator mass spectrometry with high sensitivity to track the 
fate of 33 nm 14CSiO2 NPs up to 56 d postinjection.[221] In all 
mouse tissues, the maximum concentration occurred 2 h 
postinjection via an implanted jugular vein catheter. The NPs 
showed fast clearance from the plasma and subsequent accu-
mulation in tissues, mostly in the spleen and liver, with higher 
concentrations found in the liver. Lower amounts of NPs were 
also detected in kidneys and lungs, and some in the bone 
marrow and cervical lymph nodes. NPs were not detected in 
muscle or adipose tissue, or in the brain. After 56 d, a signifi-
cant decrease of NP concentration in the kidneys and lungs was 
observed (20%), with even larger decreases in the spleen (57%) 
and liver (72%). Although the amount of NPs gradually 
decreased, a significant proportion remained in the body even 
after eight weeks. Renal clearance occurred as early as 2 h 
postinjection, as opposed to hepatobiliary clearance, which was 
observed after 21 h. Malfatti et al. postulated that NPs are 
secreted in urine via tubular secretion.[221] The size impact on 
the biodistribution of SiO2 NPs was further addressed by Xie et 
al., who tracked the fate and toxicity of 20 and 80 nm SiO2 NPs 
Figure 10. Biodistribution of mesoporous silica nanoparticles (MSNs) of different sizes: biodistribution percentages of MSNs and PEG–MSNs of 
particle sizes a) 80, b) 120, c) 200, and d) 360 nm in the heart, liver, spleen, lung, and kidney of ICR mice after tail intravenous injection at different 
time periods (30 min, 1 d, 5 d, and 1 month), respectively. Adapted with permission.[331] Copyright 2010, John Wiley & Sons.
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modified by 125I over one month, while Cho et al. investigated 
50, 100, and 200 nm rhodamine SiO2 NPs over the same time 
period.[332,333] Xie et al. showed that size had no significant 
effect on the biodistribution of the NPs and that all particles 
were mostly found in liver, spleen, and lungs (and at low con-
centrations in the blood, heart, kidneys, intestine, stomach, and 
brain). Although the distribution patterns did not differ, 
the amount of 200 nm NPs in tissues was higher. After 30 d, 
the amount of 20 nm NPs found in the liver and spleen had 
significantly decreased compared to that found for 80 nm parti-
cles.[333] Cho et al. observed all of the investigated NPs in the 
liver and spleen after four weeks, and their distribution corre-
lated with the distribution of RES within the liver and spleen. 
The concentration of the smallest NPs (50 nm) peaked in the 
urine after 12 h, while it took 24 h for the larger NPs (100 and 
200 nm). It is worth noting that both particle types are signifi-
cantly larger than the membrane pores in kidneys, thus clear-
ance by glomerular filtration cannot be expected. The same 
pattern was observed for hepatobiliary excretion, where 50 nm 
NPs were detected in feces after 24 h and 100 nm NPs after 
72 h. The 200 nm NPs were less efficiently excreted via both 
above-mentioned routes and remained mainly within the RES 
of the spleen and liver.[332] As the physicochemical properties of 
the NPs typically determine their fate in the body, the effect 
of shape on the clearance of mesoporous silica NPs has been 
investigated by Huang et al.[195] The authors used FITC- and 
PEG-functionalized nanorods: short NRs (185 nm, aspect ratio 
1.5) and long NRs (720 nm, aspect ratio 5). All NRs were 
detected in spleen and liver, and their localization correlated 
with localization of the RES. It has been observed that the fluo-
rescent signal decreased after 7 d, especially in the case of long 
NRs, which has been postulated to be due to the degradation of 
silica. Although NRs were not detected in lymph nodes and the 
brain, some were detected in kidneys. Inductively coupled 
plasma optical emission spectroscopy (ICP OES) analysis 
showed that short NRs were located predominantly in the liver 
while longer NRs were located in the spleen. PEGylation 
decreased the amount of NRs found in the liver but increased 
that found in the lungs, while slowing down the clearance. 
The short NRs were also more efficiently cleared via the urine 
and feces than long NRs. It is worth noting that, based on 
biochemical assays, NRs were observed to induce dysfunction 
in biliary excretion and glomerular filtration.[195]
The impact of the surface charge on the long-term fate and 
biodistribution of SiO2 NPs has not yet been fully studied. 
Short-term studies provide approximations of the potential 
impact of surface charge on the long-term fate of NPs.[334–336]  
By varying the NP porosity, size, and geometry, Yu et al. 
showed that surface and porosity play a more important 
role than geometry in the fate of NPs. Tissue distribution 
was found to be dependent upon the porosity and surface 
charge of the particles. Mesoporous NPs accumulated more 
in the lungs, while nonporous NPs accumulate in liver, as the 
primary amine group on the surface reduced accumula-
tion in the lungs and kidneys.[336] A recent study by Lu et al., 
who used amino- and carboxy-functionalized SiO2 NPs of 
different sizes (30, 70, and 300 nm), showed that charge—
and not size—plays a crucial role in the fate of the NPs.[335]  
Furthermore, Souris et al. also investigated SiO2 NPs of dif-
ferent charges, functionalized with a far-red-absorbing dye. 
The authors observed a signal in the liver immediately after 
injection, which was followed by a signal in the duodenum, 
indicating that hepatobiliary excretion is the preferred 
mode of clearance. Most of the fluorescence was detected in 
the feces, and ICP MS data revealed that secretion was com-
plete within 3 d.[334] Exposure can be divided into single and 
chronic exposure scenarios, as well as according to the route of 
administration, as mentioned above. Different exposure 
routes, as well as single versus repeated doses, were studied 
with 110 nm mesoporous SiO2 NPs.[337,338] The investigated 
routes of administration were intravenous, hypodermic, intra-
muscular, and oral, whereby it was shown that the highest 
tolerated dose could be achieved through oral administra-
tion. Interestingly, NPs administered orally, intramuscularly 
and hypodermically were not initially observed in the liver 
and spleen, in contrast to intravenous administration. Upon 
inspection via ICP OES, NPs were detected in the liver regard-
less of the administration route, although differential biodis-
tribution was observed. After 7 d postexposure, the amount 
of NPs in the liver and spleen increased in the case of intra-
venously administered NPs, while for oral administration a 
change was not observed. The concentrations of NPs found in 
the liver, spleen, feces, and urine increased slightly for hypo-
dermic administration.[337] In a different study, where SiO2 
NPs (20 and 100 nm) were administered orally, the NPs were 
observed in the kidneys, liver, lungs, and spleen. Elevation of 
the silica concentration in the lungs and spleen was observed 
after 2 d while the same was observed in the kidneys and liver 
after 3 d. Even 7 d after oral administration, no increased NP 
concentration was observed in the GI, esophagus, stomach, 
and intestine. Transmission electron microscopy analysis 
revealed that NPs (both sizes) were localized in the hepato-
cytes in the liver. Most of the NPs (75–80%) were excreted in 
the feces, while 7–8% were excreted via the urine. Although 
the amount of NPs was found to significantly decrease after 
7 d, longer retention was observed in the liver and kidneys 
than in the lungs and spleen, and distribution was not sig-
nificantly size dependent.[339] Retention of 150 nm NP in the 
lungs (lung air sac) and kidneys (glomerulus) was observed 
after 4 d, and the overall NP retention was 10–15%. Biodeg-
radation of these NPs was suggested since silicic acid has 
been detected. Interestingly, in some biodistribution studies 
using silica nanoparticles, NPs were observed in the cell 
nucleus.[339,340,382–384] In a repeated exposure study it was dem-
onstrated that even for potentially biodegradable NPs such 
as silica,[341] in certain cases it took longer than four weeks 
for complete clearance, while most of the NPs were found to 
persist trapped in the liver and spleen.[338] As anticipated, 
ultrasmall SiO2 NPs (2–3 nm) were predominantly and effi-
ciently excreted via the kidneys,[330] but in some cases even 
significantly larger biodegradable NPs (100 nm) were cleared 
efficiently, albeit via other routes.[341]
7.6. Polymers
A wide variety of polymers, including biological, synthetic, and 
hybrid examples, are used for a range of medical applications, 
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such as drug delivery systems, coatings, or implants.[342] They 
can be modified in their physical, chemical, and biological 
properties to be optimized for specific applications. Polymers 
can be used as building blocks for applications such as drug 
delivery systems mimicking cellular membranes and organelles 
or by imitating viral mechanisms. Next to liposomes, polymers 
have also attracted considerable attention as promising mate-
rials for medical applications since they can provide prolonged 
circulation lifetimes and controlled release of their cargo such 
as small molecules, proteins, nucleic acids, and hydrophilic and 
hydrophobic drugs.[343,382–390]
Polymer conjugates have shown promising results as therapeu-
tics in clinical trials and some have also found their way onto the 
market. Polymeric therapeutics can be subdivided into polymer–
protein and polymer–drug conjugates. The conjugation of a pro-
tein to a polymer reduces its immunogenicity while increasing 
its stability and blood circulation time.[344] Drug conjugates show 
improved aqueous solubility, increased blood circulation time, 
reduced toxicity, and an improved therapeutic index through 
linkage to polymers.[345,346] However, since both subgroups show 
binding via a single linker and limited binding sites, the loading 
of the conjugates is reduced compared to vesicular structures.
Several protein–polymer conjugates have already been used 
for clinical trials. The first conjugate approved for the treat-
ment of acute lymphoblastic leukemia (ALL) by the FDA was 
PEGylated-asparaginase in 1994, better known by the name 
Pegaspargase or Oncaspar.[347,348] Data from pediatric and adult 
clinical trials show that the elimination half-life of Pegaspar-
gase is ≈5.5–6 d, about five times longer than non-PEGylated 
asparaginase derived from Escherichia coli.[349] Deamination 
of asparagine occurred 2 h after intravenous application of a 
dose of 2000 IU m−2 Pegaspargase and sustained up to three 
weeks in adult ALL patients, and about five weeks a dose 
of 2500 IU m−2 was given to pediatric ALL patients.[350,351] 
Single intravenous infusion of 500, 750, 1000, or 2500 IU m−2  
Pegaspargase revealed that asparaginase activity levels 
remained >0.1 IU mL−1 in 60%, 40%, and 20% of patients 
two weeks after treatment with 2500, 1000, and 500 IU m−2  
Pegaspargase, respectively, but the levels became undetectable 
after three weeks in all cases.[352] As also seen with liposomes, 
PEGylation is a commonly used technique to improve in vivo 
biodistribution of bioactive molecules or whole drug delivery 
systems. This technique supports the blockage of potentially 
immunogenic epitopes, thus reducing the dose-limiting hyper-
sensitivity reactions associated with native asparaginase delays 
in the clearance by the RES.[353,354] Despite this fact, rapid clear-
ance of Pegaspargase has been reported in up to one-third of 
patients treated for ALL. Hypersensitivity reactions to Pegas-
pargase lead to the formation of antibodies against PEG.[355]  
Therefore, screening for anti-PEG antibodies may allow 
the modification of the dosing strategy or the use of a non-
PEGylated drug version to overcome clearance. Further 
polymer–protein conjugates available in the market involve, 
e.g., the antitumor protein neocarzinostatin linked to styrene 
maleic anhydride, known as Zinostatin, for the treatment of 
hepatocellular carcinoma, interferon-α linked to PEG (PEGasys) 
for hepatitis C treatment, the protein adenosine deaminase 
linked to PEG (Adagen) for the treatment of severe combined 
immunodeficiency, and granulocyte colony-stimulating factor 
linked to PEG (Neulasta) for neutropenia prevention associated 
with chemotherapy.[356–359] Numerous clinical trials of novel 
polymer–protein conjugates including enzymes and biological 
response modifiers have been performed or are ongoing.[360–363] 
Maeda investigated the tumor and tissue distribution of poly 
(maleic acid–styrene)-conjugated neocarzinostatin (Zinostatin) 
24 h after intravenous injection in mice. In comparison to its 
nonconjugated form, the polymer-conjugated neocarzinostatin 
revealed fivefold higher concentration in the tumor tissue 
and tenfold and sixfold higher concentrations in the liver and 
spleen, respectively, compared to the tumor tissue.[356] Take-
shita et al. investigated the organ specificity of the same formu-
lation in rats. After intravenous injection, the drug was found 
in the kidney, lymph nodes, and bladder in very high concen-
trations, and in lesser concentrations in the bone marrow, 
lung, small intestine, liver, and spleen.[364] In addition, Maeda 
showed that due to albumin binding, the half-life of poly(maleic 
acid–styrene)-conjugated neocarzinostatin increased to 19 min 
compared to 1.9 min for naked neocarzinostatin in mice.[356] Due 
to its very short half-life, long term studies of poly(maleic acid–
styrene)-conjugated neocarzinostatin do not exist. Further thera-
peutic applications of styrene–maleic acid copolymer conjugates 
involve the linkage to pirarubicin, revealing a 8.4-fold increase 
in tumor tissue accumulation compared to free pirarubicin.[365] 
After 72 h the concentration of the polymer conjugate found in 
the liver, spleen, and kidney decreased to 24.5%, 27%, and 19% 
compared to that observed at 24 h. In contrast to all other tissues, 
the concentration of the polymer conjugate in the tumor after 
72 h remained 75% of that observed at 24 h, which was the 
highest concentration, followed by the liver, spleen, and kidney.
Polymer–drug conjugates have already been studied for 
more than 30 years, with increasing numbers of applications 
entering clinical trials. However, so far no polymer–drug con-
jugates have been approved.[366] Several biodistribution studies 
have been published, mainly focusing on early time points (less 
than one week; see Table 4).[367–369] Borgman et al. investigated 
the biodistribution of 125I-radiolabeled N-(2-hydroxypropyl)
methacrylamide (HPMA) copolymer–geldanamycin-RGDfK 
conjugates in mice to improve geldanamycin chemotherapy 
by reducing unspecific toxicity and improving tumor response 
through higher localized concentrations of the drug.[370]  
Time-dependent biodistribution studies were carried out after 
1, 6, 24, 48, and 72 h postinjection. Rapid blood clearance was 
observed with very little activity remaining in blood after 24 h. 
It has been shown that the dose of the polymer received by the 
tumor at 1 h was retained, with a modest increase between 1 
and 24 h, as well as prolonged accumulation of the polymer–
drug conjugate for the duration of the study. At 24 h, the 
tumor accumulation was significantly higher than in the blood, 
heart, lung, spleen, and stomach. Additionally, the accumula-
tion in the tumor after 72 h was significantly higher than all 
organs except the kidneys (see Figure 11). Etrych et al. inves-
tigated the effects of the molecular weight and architecture of 
HPMA copolymer–doxorubicin conjugates on biodistribution 
and in vivo activity.[371] Copolymer–doxorubicin conjugates of 
linear and star architectures were compared. With increasing 
molecular weight (MW), renal clearance decreased, and the 
conjugates displayed extended blood circulation and enhanced 
tumor accumulation, which resulted in significantly improved 
23
htt
p:/
/do
c.r
ero
.ch
anti-tumor activities. The linear conjugates with flexible polymer 
chains were eliminated by kidney clearance more quickly. 
Only star conjugates with MWs below 50 000 Da were removed 
by kidney filtration, while linear polymer conjugates with 
MWs near 70 000 Da were detected in the urine 36–96 h after 
injection. Falzarano et al. investigated PMMA/N-isopropyl-
acrylamide polymer NPs, administered both intraperitoneally 
and orally, delivering antisense oligonucleotides for the treat-
ment of Duchenne muscular dystrophy.[372] After a single IP 
administration, the polymers remained mainly in the peritoneal 
cavity for about 24 h and then diffused throughout the whole 
body, whereas the fluorescence persisted for up to 22 d. Multiple 
administrations of the polymers for up to two months led to bio-
distribution in all muscles, including the heart, and revealed a 
fluorescence signal until 60 d. The fluorescence, while absent 
in the liver, persisted in kidneys, spleen, and lymph nodes. 
Although many polymer–drug conjugates based on chemistries 
such as PEG or HPMA have progressed into clinical develop-
ment, their progression toward market approval has undoubt-
edly been hindered by their nonbiodegradable nature. High-MW 
polymer carriers exceeding the renal excretion threshold should 
be biodegradable to prevent long-term retention in the body.
8. Outlook and Conclusion
In order to take advantage of the full potential of nanomaterials 
for medical applications it is essential to have a profound (fun-
damental) comprehension of the interactions of such materials 
on the level of single cells, tissue barriers, and the human body 
as whole. While many studies have been performed to investi-
gate and develop potential nanomaterials for application in drug 
delivery or as theranostic devices, their biodistribution and long-
term fate, although crucial for drug applicability as well as effi-
cacy, have only rarely been investigated. This is also especially 
important if one considers a repeated use of such nanomedicines 
over a prolonged time period. One possible hurdle for the rela-
tively low number of studies might be the difficulty in accessing 
reproducible and reliable analytical methods for the intracel-
lular-, tissue-, and organ-specific quantification of nanomaterials. 
Up to date no standardized and validated method is recom-
mended, also because of the very different requirements of the 
analytical procedure depending on the particle type in combina-
tion with the different specifications and limitations for each of 
the analytical techniques.[373,374]
The biodistribution and clearance of a specific nanoma-
terial depends not only on the physicochemical properties 
of the materials but also on how the material is applied to a 
(human) body. Although there seems to be an agreement that 
size and surface charge are the most important determinants 
of a material’s fate in vivo, a grouping of the materials is not 
yet possible due to the variety of approaches applied to nano-
material synthesis. This results in differing surface struc-
tures, which can strongly affect the interaction of a material 
with physiological fluids, cells, and organs. However, several 
efforts are being made to harness the advantages of nanosized 
systems for medical applications Instead of trying to exploit 
the particles’ inherent properties, some researchers focus 
very successfully on them as efficient nanocarriers for drug 
delivery. Through combination with nanotechnology, some 
Table 4. Long-term biodistribution data on polymeric nanomaterials.
Material Size [nm] Animal Investigated tissuea) Longest timepoint Reference
PEG-asparaginase N/A Human Bl 21 d [352]
Zinostatin N/A Mouse TT, Li, S 24 h [356]
Styrene–maleic acid 
copolymer-conjugated 
pirarubicin
18.9 ± 10.0 Mouse TT, Li, S, K 72 h [365]
HPMA copolymer–
geldanamycin-RGDfK
N/A Mouse Bl, TT, H, L, Li, S, St, K 72 h [370]
HPMA 
copolymer–doxorubicin
N/A Mouse Bl, U, Li, TT 96 h [371]
PMMA/N-isopropyl-
acrylamide
130 Mouse Li, K, S, H, LN 22 d [372]
HPMA 
copolymer–doxorubicin
N/A Mouse Bl, S, Li, K, TT, H 168 h [385]
HPMA copolymer–
9-aminocamptothecin
N/A Mouse L, H, Li, S, K, SI, C, Co 24 h [386]
(HPMA) 
copolymer–dexamethasone
N/A Rat Bl, H, L, K, L, S, J 7 d [387]
PVP-TNF-α N/A Mouse Bl 3 h [388]
Camptothecin–polymer 
conjugate IT-101
N/A Mouse and rat Bl, Li, S, L, TT, H 48 h [389]
Etoposide-loaded PLGA 105; 160 Mouse H, L, Li, S, K, St, SI, M, Br 24 h [390]
a)TT: tumor tissue; H: heart; L: lung; K: kidney; Br: brain; M: muscle; SI: small intestine; Bl: blood; Li: liver; S: spleen; J: joints; St: stomach; C: cecum; Co: colon; U: urine; 
LN: lymph nodes; N/A: data not available; and bold letters indicate that the organ tested positive for nanoparticles.
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key medical features of drugs (i.e., half-life, solubility, and tox-
icity) can be improved.[375] Examples that are now routinely 
used in clinics consist of liposomal-encapsulated doxorubicin 
(Doxil), paclitaxel-loaded albumin nanoparticles (Abraxane), 
or polymeric micelles containing paclitaxel (Genexol PM).[376] 
Hence, in order to promote the safe-by-design approach of 
biomedical nanomaterials, nanoscience researchers should 
focus future research on studies of the long-term effects of 
nanomaterials in the human body and their possible chronic 
effects. A special emphasis must also be placed on detailed 
reporting of the nanomaterial’s properties as well as the bio-
logical systems used. Taking into account that data collec-
tion in long-term studies requires a significant amount of 
time, and also considering ethical issues for in vivo studies, 
it is recommended that the methodology should be stand-
ardized and follow published and accepted guidelines as 
much as possible in order to make studies comparable. 
Additionally, (novel) analytical methods should be devel-
oped and optimized to allow detection and quantification 
of the distribution of nanomaterials in cells, tissues, and/
or organs.
Acknowledgements
J.B., A.M., D.H., and R.L. contributed equally to this work. The authors 
would like to acknowledge the Swiss National Science Foundation 
(310030_159847/1), the National Center of Competence in Research for 
Bio-Inspired Materials, and the Adolphe Merkle Foundation for ﬁnancial 
support. The authors kindly thank Dr. Miguel Spuch Calvar for the 
graphical designs.
Conﬂict of Interest
The authors declare no conﬂict of interest.
Keywords
biodistribution, clearance, long-term fate, nanomaterials, routes of 
exposure
Received: July 31, 2017
Revised: October 20, 2017
Published online: 
Figure 11. Biodistribution of 125I-radiolabeled HPMA copolymer–AH-GDM conjugates: A,B) biodistribution of 125I-radiolabeled HPMA copolymer–AH-GDM 
conjugates with (A) and without (B) RGDfK in prostate-tumor-bearing mice. Activity per organ is expressed as % injected dose per gram of tissue (% ID g−1) 
following necropsy at 1, 24, 48, and 72 h postintravenous injection. Rapidly decreasing blood concentrations are observed with no signiﬁcant accumulation 
differences in normal organs. Signiﬁcantly higher localization of the targeted conjugate occurs in the tumor after 1 h compared with the nontargeted conju-
gate, as indicated in the graph as *p < 0.05. Data are expressed as mean ± SD. Reproduced with permission.[370] Copyright 2009, American Chemical Society.
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